Hippo (HIPO) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 04, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-39711
Entity Registrant Name	HIPPO HOLDINGS INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0662604
Entity Address, Address Line One	150 Forest Avenue
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94301
City Area Code	650
Local Phone Number	294-8463
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		562,663,119
Entity Central Index Key	0001828105
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	HIPO
Security Exchange Name	NYSE
Warrants to purchase common stock
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase common stock
Trading Symbol	HIPO.WS
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Investments:
Fixed maturities available-for-sale, at fair value (amortized cost: $60.1 million and $55.9 million, respectively)	$ 59.7	$ 56
Short-term investments	12.3	0
Total investments	72	56
Cash and cash equivalents	778.7	452.3
Restricted cash	44.1	40.1
Accounts receivable, net of allowance of $0.4 million and $0.5 million, respectively	60.3	37.1
Reinsurance recoverable on paid and unpaid losses and LAE	279.4	134.1
Prepaid reinsurance premiums	228.1	129.4
Ceding commissions receivable	38	21.3
Capitalized internal use software	21.6	14.7
Goodwill	53.2	47.8
Intangible assets	33.7	33.9
Other assets	49.1	12.7
Total assets	1,658.2	979.4
Liabilities:
Loss and loss adjustment expense reserve	239.7	105.1
Unearned premiums	244.3	150.3
Reinsurance premiums payable	162.1	86.1
Provision for commission	11.2	28.2
Fiduciary liabilities	23.8	17.5
Convertible promissory notes	0	273
Derivative liability on notes	0	113.3
Contingent consideration liability	11.5	12
Preferred stock warrant liabilities	0	22.9
Accrued expenses and other liabilities	61.9	25.7
Total liabilities	754.5	834.1
Commitments and contingencies (Note 12)
Convertible preferred stock:
Preferred stock, $0.0001 par value per share; 10,000,000 and 323,232,460 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 0 and 305,887,443 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively; Liquidation preferences of $0 and $359.4 million as of September 30, 2021 and December 31, 2020, respectively	0	344.8
Stockholders’ equity (deficit)
Common stock, $0.0001 par value per share; 2,000,000,000 and 582,981,484 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 562,873,880 and 92,547,014 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	0	0
Additional paid-in capital	1,469.1	56.9
Accumulated other comprehensive (loss) income	(0.4)	0.1
Accumulated deficit	(567.3)	(256.6)
Total Hippo stockholders' equity (deficit)	901.4	(199.6)
Noncontrolling interest	2.3	0.1
Total stockholders’ equity (deficit)	903.7	(199.5)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)	$ 1,658.2	$ 979.4

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Fixed maturities, available-for-sale, amortized cost	$ 60.1	$ 55.9
Accounts receivable, allowance	$ 0.4	$ 0.5
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized (in shares)	10,000,000	323,232,460
Convertible preferred stock, shares issued (in shares)	0	305,887,443
Convertible preferred stock, shares outstanding (in shares)	0	305,887,443
Convertible preferred stock, liquidation preference	$ 0	$ 359.4
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	2,000,000,000	582,981,484
Common stock, shares issued (in shares)	562,873,880	92,547,014
Common stock, shares outstanding (in shares)	562,873,880	92,547,014

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Net earned premium	$ 10.9	$ 4.7	$ 29.9	$ 8.7
Commission income, net	6.6	6.3	18.2	21.8
Service and fee income	3.7	1.8	10.8	3.9
Net investment income	0.1	0.2	0.2	0.8
Total revenue	21.3	13	59.1	35.2
Expenses:
Losses and loss adjustment expenses	26.3	8.7	65	13.9
Insurance related expenses	7.1	5.2	23.2	13
Technology and development	8.3	5.7	22.7	13.2
Sales and marketing	22.4	17.6	69.3	52.9
General and administrative	13.4	16.2	30.6	27.3
Interest and other (income) expense	(26.4)	0.1	156.5	4.2
Total expenses	51.1	53.5	367.3	124.5
Loss before income taxes	(29.8)	(40.5)	(308.2)	(89.3)
Income taxes (benefit) expense	0.1	(1.9)	0.4	(1.9)
Net loss	(29.9)	(38.6)	(308.6)	(87.4)
Net income attributable to noncontrolling interests, net of tax	1	0	2.1	0
Net loss attributable to Hippo	(30.9)	(38.6)	(310.7)	(87.4)
Other comprehensive income:
Change in net unrealized gain or loss on investments, net of tax	(0.1)	(0.2)	(0.4)	(0.2)
Comprehensive loss attributable to Hippo	(31)	(38.8)	(311.1)	(87.6)
Per share data:
Net loss attributable to Hippo - basic	(30.9)	(38.6)	(310.7)	(87.4)
Net loss attributable to Hippo - diluted	$ (30.9)	$ (38.6)	$ (310.7)	$ (87.4)
Weighted-average shares used in computing net loss per share attributable to Hippo - basic (in shares)	386,882,408	87,383,796	175,690,513	85,864,640
Weighted-average shares used in computing net loss per share attributable to Hippo - diluted (in shares)	386,882,408	87,383,796	175,690,513	85,864,640
Net loss per share attributable to Hippo - basic (in dollars per share)	$ (0.08)	$ (0.44)	$ (1.77)	$ (1.02)
Net loss per share attributable to Hippo - diluted (in dollars per share)	$ (0.08)	$ (0.44)	$ (1.77)	$ (1.02)

Consolidated Statements of Chan

Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($) $ in Millions	Total	Preferred D Stock	Preferred E Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Hippo Stockholders' Equity (Deficit )	Non controlling Interests
Beginning balance (in shares) at Dec. 31, 2019	250,604,066
Beginning balance at Dec. 31, 2019	$ 190.3
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred stock, net of issuance costs (in shares)		2,235,226
Issuance of preferred stock, net of issuance costs		$ 4.9
Ending balance (in shares) at Mar. 31, 2020	252,839,292
Ending balance at Mar. 31, 2020	$ 195.2
Beginning balance (in shares) at Dec. 31, 2019				83,936,969
Beginning balance at Dec. 31, 2019	(78.3)			$ 0	$ 36.7	$ 0.1	$ (115.1)	$ (78.3)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(23.9)						(23.9)	(23.9)
Other comprehensive income (loss)	0.2					0.2		0.2
Issuance of common stock upon exercise of stock options (in shares)				575,102
Issuance of common stock upon exercise of stock options	0.1				0.1			0.1
Vesting of early exercised stock options (in shares)				269,091
Vesting of early exercised stock options	0				0			0
Vesting of restricted stock awards (in shares)				73,417
Stock-based compensation expense	1				1			1
Other	0.1								0.1
Ending balance (in shares) at Mar. 31, 2020				84,854,579
Ending balance at Mar. 31, 2020	$ (100.8)			$ 0	37.8	0.3	(139)	(100.9)	0.1
Beginning balance (in shares) at Dec. 31, 2019	250,604,066
Beginning balance at Dec. 31, 2019	$ 190.3
Ending balance (in shares) at Sep. 30, 2020	305,887,443
Ending balance at Sep. 30, 2020	$ 344.8
Beginning balance (in shares) at Dec. 31, 2019				83,936,969
Beginning balance at Dec. 31, 2019	(78.3)			$ 0	36.7	0.1	(115.1)	(78.3)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(87.4)
Ending balance (in shares) at Sep. 30, 2020				88,754,776
Ending balance at Sep. 30, 2020	$ (149.4)			$ 0	53.1	(0.1)	(202.4)	(149.4)	0
Beginning balance (in shares) at Mar. 31, 2020	252,839,292
Beginning balance at Mar. 31, 2020	$ 195.2
Ending balance (in shares) at Jun. 30, 2020	252,839,292
Ending balance at Jun. 30, 2020	$ 195.2
Beginning balance (in shares) at Mar. 31, 2020				84,854,579
Beginning balance at Mar. 31, 2020	(100.8)			$ 0	37.8	0.3	(139)	(100.9)	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(24.9)						(24.8)	(24.8)	(0.1)
Other comprehensive income (loss)	(0.2)					(0.2)		(0.2)
Issuance of common stock upon exercise of stock options (in shares)				1,798,897
Issuance of common stock upon exercise of stock options	0.5				0.5			0.5
Vesting of restricted stock awards (in shares)				34,772
Stock-based compensation expense	1				1			1
Ending balance (in shares) at Jun. 30, 2020				86,688,248
Ending balance at Jun. 30, 2020	$ (124.4)			$ 0	39.3	0.1	(163.8)	(124.4)	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred stock, net of issuance costs (in shares)			53,048,151
Issuance of preferred stock, net of issuance costs			$ 149.6
Ending balance (in shares) at Sep. 30, 2020	305,887,443
Ending balance at Sep. 30, 2020	$ 344.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(38.6)						(38.6)	(38.6)
Other comprehensive income (loss)	(0.2)					(0.2)		(0.2)
Issuance of common stock upon exercise of stock options (in shares)				2,038,968
Issuance of common stock upon exercise of stock options	0.5				0.5			0.5
Vesting of early exercised stock options (in shares)				0
Vesting of early exercised stock options	0				0			0
Vesting of restricted stock awards (in shares)				27,560
Stock-based compensation expense	13.3				13.3			13.3
Ending balance (in shares) at Sep. 30, 2020				88,754,776
Ending balance at Sep. 30, 2020	$ (149.4)			$ 0	53.1	(0.1)	(202.4)	(149.4)	0
Beginning balance (in shares) at Dec. 31, 2020	305,887,443	45,860,183	53,048,151
Beginning balance at Dec. 31, 2020	$ 344.8	$ 99.8	$ 149.7
Ending balance (in shares) at Mar. 31, 2021	305,887,443
Ending balance at Mar. 31, 2021	$ 344.8
Beginning balance (in shares) at Dec. 31, 2020				92,547,014
Beginning balance at Dec. 31, 2020	(199.5)			$ 0	56.9	0.1	(256.6)	(199.6)	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(194.9)						(195.2)	(195.2)	0.3
Other comprehensive income (loss)	(0.6)					(0.6)		(0.6)
Issuance of common stock upon exercise of stock options (in shares)				4,604,469
Issuance of common stock upon exercise of stock options	1.9				1.9			1.9
Vesting of early exercised stock options (in shares)				171,695
Vesting of early exercised stock options	0.2				0.2			0.2
Repurchase of common stock (in shares)				(21,732)
Stock-based compensation expense	2.9				2.9			2.9
Other	0						(0.1)	(0.1)	0.1
Ending balance (in shares) at Mar. 31, 2021				97,301,446
Ending balance at Mar. 31, 2021	$ (390)			$ 0	61.9	(0.5)	(451.9)	(390.5)	0.5
Beginning balance (in shares) at Dec. 31, 2020	305,887,443	45,860,183	53,048,151
Beginning balance at Dec. 31, 2020	$ 344.8	$ 99.8	$ 149.7
Ending balance (in shares) at Sep. 30, 2021	0
Ending balance at Sep. 30, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020				92,547,014
Beginning balance at Dec. 31, 2020	(199.5)			$ 0	56.9	0.1	(256.6)	(199.6)	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (308.6)
Issuance of common stock upon exercise of stock options (in shares)	20,728,860
Ending balance (in shares) at Sep. 30, 2021				562,873,880
Ending balance at Sep. 30, 2021	$ 903.7			$ 0	1,469.1	(0.4)	(567.3)	901.4	2.3
Beginning balance (in shares) at Mar. 31, 2021	305,887,443
Beginning balance at Mar. 31, 2021	$ 344.8
Ending balance (in shares) at Jun. 30, 2021	305,887,443
Ending balance at Jun. 30, 2021	$ 344.8
Beginning balance (in shares) at Mar. 31, 2021				97,301,446
Beginning balance at Mar. 31, 2021	(390)			$ 0	61.9	(0.5)	(451.9)	(390.5)	0.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(83.7)						(84.5)	(84.5)	0.8
Other comprehensive income (loss)	0.2					0.2		0.2
Issuance of common stock upon exercise of stock options (in shares)				1,283,582
Issuance of common stock upon exercise of stock options	0.6				0.6			0.6
Vesting of early exercised stock options (in shares)				171,675
Vesting of early exercised stock options	0.2				0.2			0.2
Stock-based compensation expense	3.1				3.1			3.1
Other	0
Ending balance (in shares) at Jun. 30, 2021				98,756,703
Ending balance at Jun. 30, 2021	$ (469.6)			$ 0	65.8	(0.3)	(536.4)	(470.9)	1.3
Increase (Decrease) in Temporary Equity [Roll Forward]
Exercise of preferred stock warrant (in shares)	17,344,906
Exercise of preferred stock warrant	$ 173.4
Convertible preferred stock conversion (in shares)	(323,232,349)
Convertible preferred stock conversion	$ (518.2)
Ending balance (in shares) at Sep. 30, 2021	0
Ending balance at Sep. 30, 2021	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(29.9)						(30.9)	(30.9)	1
Other comprehensive income (loss)	(0.1)					(0.1)		(0.1)
Convertible preferred stock conversion (in shares)				323,232,349
Convertible preferred stock conversion	518.2				518.2			518.2
Convertible debt conversion and other issuances (in shares)				43,449,312
Convertible debt conversion and other issuances	434.5				434.5			434.5
Issuance of common stock in connection with the Business Combination, net (in shares)				54,988,620
Issuance of common stock in connection with the Business Combination, net	452.9				452.9			452.9
Acquisition of Public and Private Placement Warrants	(14.6)				(14.6)			(14.6)
Issuance of common stock in an acquisition (in shares)				1,117,688
Issuance of common stock in an acquisition	5.9				5.9			5.9
Issuance of common stock upon exercise of stock options (in shares)				14,126,637
Issuance of common stock upon exercise of stock options	1.3				1.3			1.3
Vesting of early exercised stock options (in shares)
Vesting of early exercised stock options	0.2				0.2			0.2
Exercise of common stock warrants, net (in shares)				27,202,571
Stock-based compensation expense	4.9				4.9			4.9
Ending balance (in shares) at Sep. 30, 2021				562,873,880
Ending balance at Sep. 30, 2021	$ 903.7			$ 0	$ 1,469.1	$ (0.4)	$ (567.3)	$ 901.4	$ 2.3

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (308.6)	$ (87.4)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7.7	4.8
Share–based compensation expense	9.8	15
Change in fair value of preferred stock warrant liabilities	121.6	4.2
Change in fair value of contingent consideration liability	2.1	1.8
Change in fair value of derivative liability on notes	61.4	0
Amortization of debt discount	20.4	0
Gain on extinguishment of debt	(47)	0
Change in fair value of warrant liability	(5.6)	0
Non-cash service expense	7	0
Other	6.6	0.8
Changes in assets and liabilities:
Accounts receivable, net	(22.4)	(24.3)
Reinsurance recoverable on paid and unpaid losses and LAE	(145.3)	(27.7)
Ceding commissions receivable	(16.7)	(0.4)
Prepaid reinsurance premiums	(98.7)	(11)
Other assets	(32.6)	(8.7)
Provision for commission	(16.9)	7.2
Fiduciary liabilities	6.4	10.1
Accrued expenses and other liabilities	19	0.9
Loss and loss adjustment expense reserves	134.6	31.2
Unearned premiums	94	24.9
Reinsurance premiums payable	76.1	22.3
Net cash used in operating activities	(127.1)	(36.3)
Cash flows from investing activities:
Capitalized internal use software costs	(1.4)	(6.5)
Purchase of intangible assets	(3.3)	0
Purchases of property and equipment	(0.1)	(0.4)
Purchases of investments	(24.8)	0
Maturities of investments	2	74.9
Sales of investments	5.6	28.6
Cash paid for acquisitions, net of cash acquired	(0.6)	(71.8)
Other	(0.3)	0
Net cash (used in) provided by investing activities	(22.9)	24.8
Cash flows from financing activities:
Proceeds from the exercise of preferred stock warrants	29	0
Proceeds from reverse recapitalization, net of redemptions, secondaries and costs	449.3	0
Proceeds from exercise of options	3.9	1
Payments of contingent consideration	(1.8)	(3.2)
Net cash provided by financing activities	480.4	152.4
Net increase in cash, cash equivalents, and restricted cash	330.4	140.9
Cash, cash equivalents, and restricted cash at the beginning of the period	492.4	42
Cash, cash equivalents, and restricted cash at the end of the period	822.8	182.9
Supplemental disclosures of non-cash financing and investing activities:
Conversion of preferred stock for common stock	518.3	0
Acquisition of public and private placement warrants	14.6	0
Equity issued for acquisitions	5.9	0
Unpaid transaction costs	2.3	0
Preferred D Stock
Cash flows from financing activities:
Proceeds from preferred shares, net of issuance costs	0	4.9
Preferred E Stock
Cash flows from financing activities:
Proceeds from preferred shares, net of issuance costs	$ 0	$ 149.7

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Summary of Significant Accounting Policies	1. Description of Business and Summary of Significant Accounting Policies Description of Business Hippo Holdings Inc., referred to herein as “Hippo,” the “Company” was originally incorporated under the name Reinvent Technology Partners Z (“RTPZ”), a Cayman Islands exempted company, on October 2, 2020 for the purpose of effecting a merger, capital stock-exchange, asset acquisition, share purchase, reorganization, or similar business combination. On August 2, 2021, RTPZ domesticated as a Delaware corporation and changed its name to “Hippo Holdings Inc.” (the “Domestication”) and consummated the merger (the “First Merger”) of RTPZ Merger Sub Inc. (“Merger Sub”), a Delaware corporation and subsidiary of RTPZ, with and into Hippo Enterprises Inc., a Delaware corporation (“Old Hippo”), with Old Hippo surviving the Merger as a wholly owned subsidiary of the Company immediately following the First Merger, Old Hippo (as the surviving corporation of the First Merger) was merged with and into the Company, with the Company surviving (the “Second Merger” and, together with the First Merger, the “Mergers” or the “Business Combination”). The Business Combination was completed pursuant to the terms of the Agreement and Plan of Merger, dated as of March 3, 2021, by and among RTPZ, Merger Sub and Old Hippo. For additional information on the Business Combination, refer to Note 2. The Company’s subsidiary, Hippo Analytics Inc., is a licensed insurance agency that provides various insurance services, including some or all of the following services for affiliated and non-affiliated insurance carriers: soliciting, marketing, servicing, underwriting, or providing claims processing services for a variety of commercial and personal insurance products. The Company’s insurance company subsidiaries, Spinnaker Insurance Company (Spinnaker), an Illinois domiciled insurance company, and Spinnaker Specialty Insurance Company (Spinnaker Specialty), a Texas domiciled authorized surplus lines insurance company, underwrite personal and commercial insurance products on a direct basis through licensed insurance agents and surplus lines brokers. Hippo Analytics Inc. offers its insurance products through licensed insurance agents, and direct-to-consumer channels. The insurance products offered through Hippo Analytics Inc. primarily include homeowners’ insurance policies that protect customers from the risks of fire, wind, and theft. Hippo Analytics Inc. is licensed as an insurance agency in 50 states and the District of Columbia and currently underwrites and distributes policies in 37 states as a managing general agent. The Company’s other non-insurance subsidiaries offer service contracts, home health check-ups, and home care advice. The Company’s headquarters are located in Palo Alto, California. In August 2020, Old Hippo acquired Spinnaker, which is a licensed property casualty carrier in all 50 states and the District of Columbia. Beginning in September 2020, in connection with the acquisition of Spinnaker, the Company also retains portions of direct insurance risk for programs underwritten by third parties. The amount of risk retention is varied across the different programs. We retain approximately 11% of the proportional risk through Spinnaker or RHS. Basis of Presentation and Consolidation The interim condensed consolidated financial statements are presented in accordance with Generally Accepted Accounting Principles (“GAAP”) and include the Company’s consolidated subsidiaries. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements and accompanying footnotes should be read in conjunction with the audited consolidated financial statements of RTPZ and Old Hippo as of and for the year ended December 31, 2020 presented in the Company’s Registration Statement on Form S-1 (File No. 333-259040) filed with the SEC on August 24, 2021. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company’s significant accounting policies, compared to the accounting policies described in Note 1, Description of Business and Summary of Significant Accounting Policies, in the Notes to Old Hippo’s Consolidated Financial Statements as of and for for the year ended December 31, 2020 presented in the Company’s Registration Statement on Form S-1 (File No. 333-259040) filed with the SEC on August 24, 2021. As a result of the Business Combination, which was completed on August 2, 2021, prior period share and per share amounts presented in the accompanying Unaudited Condensed Consolidated Financial Statements and these related notes have been converted in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. Refer to Note 2 for additional information. All intercompany transactions have been eliminated in consolidation. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. The interim financial information is unaudited, but reflects all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. Interim results are not necessarily indicative of the results for a full year. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include, but are not limited to, loss and loss adjustment expense (“LAE”) reserves, provision for commission slide and cancellations, reinsurance recoverable on unpaid losses and LAE, the fair values of investments, common stock, stock-based awards, warrant liabilities, contingent consideration liabilities, embedded derivative liabilities, acquired intangible assets and goodwill, deferred tax assets and uncertain tax positions, and revenue recognition. The Company evaluates these estimates on an ongoing basis. These estimates are informed by experience and other assumptions that the Company believes are reasonable under the circumstances. Actual results may differ significantly from these estimates. Business Combination The Company accounts for acquisitions of entities or asset groups that qualify as businesses using the acquisition method of accounting in accordance with ASC 805, Business Combinations. Purchase consideration is allocated to the tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date, which are measured in accordance with the principles outlined in ASC 820, Fair Value Measurement. The determination of fair value requires management to make estimates about discount rates, future expected cash flows, market conditions and other future events that are highly subjective in nature. The excess of the total purchase consideration over the fair value of the identified net assets acquired is recognized as goodwill. The results of the acquired businesses are included in the results of operations beginning from the date of acquisition. Acquisition-related costs are expensed as incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the allocation of purchase consideration and to the fair values of assets acquired and liabilities assumed to the extent that additional information becomes available. After this period, any subsequent adjustments are recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss). The Business Combination on August 2, 2021 was accounted for as a reverse recapitalization. See Note 2 for additional information. Emerging Growth Company The Company currently qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 and is provided the option to adopt new or revised accounting guidance either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. The Company has elected to adopt new or revised accounting guidance within the same time period as private companies, unless, indicated below, management determines it is preferable to take advantage of early adoption provisions offered within the applicable guidance. Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted Internal-Use Software In August 2018, the FASB issued ASU No. 2018-15, Intangibles — Goodwill and Other — Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract . The intent of this pronouncement is to align the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software as defined in ASC 350-40. ASU 2018-15 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted this new guidance on a prospective basis on January 1, 2021. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) . Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of future lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). This ASU is effective for annual reporting periods beginning after December 15, 2021, and interim reporting periods beginning after December 15, 2022. Under this guidance, we will record assets and liabilities relating primarily to our long-term office leases. The Company currently is computing the impact of Topic 842 on our consolidated financial statements and do not expect to have a material impact on the Company’s consolidated statements of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), and subsequent related ASUs, which amends the guidance on the impairment of financial instruments by requiring measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for fiscal years, and for interim periods within the fiscal years, beginning after December 15, 2022. The Company is currently evaluating the impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. This ASU will be effective for annual periods beginning after December 15, 2020, and interim periods beginning after December 15, 2020. ASU 2019-12 will be effective for private entities for annual periods beginning after December 15, 2021, and interim periods beginning after December 15, 2022, with early adoption permitted. The Company expects to adopt ASU 2019-12 under the private company transition guidance beginning January 1, 2022 and does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the timing of adoption and the impact on the consolidated financial statements.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combinations	2. Business Combinations Business Combination - Reverse Recapitalization On August 2, 2021, the Company completed the Business Combination (the “Closing”). The Business Combination was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with GAAP. Under this method of accounting, RTPZ was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the reverse recapitalization was treated as the equivalent of Old Hippo issuing stock for the net assets of RTPZ, accompanied by a recapitalization. Operations prior to the reverse recapitalization were those of Old Hippo. In connection with the Business Combination: • Certain accredited investors (the “PIPE Investors”) entered into subscription agreements (the “PIPE Subscription Agreements”) pursuant to which the PIPE Investors agreed to purchase 55,000,000 shares (the “PIPE Shares”) of the Company’s common stock at a purchase price per share of $10.00 and an aggregate purchase price of $550.0 million (the “PIPE Investment”). The PIPE Investment was consummated concurrently with the Closing. • Hippo used $95.0 million to reacquire 9,500,000 shares of common stock from certain stockholders of Old Hippo prior to the Business Combination. • Prior to the Business Combination, RTPZ issued an aggregate of 5,750,000 shares of Class B common stock (the “Founder Shares”) to Reinvent Sponsor Z LLC, a Cayman Islands limited liability company (the “Sponsor”) for an aggregate purchase price of $25,000 in cash. All outstanding Founder Shares were automatically converted into shares of the Company’s common stock on a one-for-one basis at the Closing and will continue to be subject to the transfer restrictions applicable to such Founder Shares. • Prior to the Closing, holders of 19,261,380 shares of Class A common stock of RTPZ exercised their rights to redeem those shares for cash at an approximate price of $10.00 per share, for an aggregate of approximately $192.6 million which was paid to such holders at Closing. The remaining Class A common stock of RTPZ converted into shares of the Company’s common stock on a one-for-one basis at the Closing. • Immediately after giving effect to the Merger and the PIPE Investment, there were 559,731,226 shares of Hippo common stock outstanding. The aggregate gross cash consideration received by the Company in connection with the Business Combination and the PIPE investment was $587.7 million, which consisted of proceeds of $550.0 million from the PIPE Investment, plus approximately $37.7 million of cash from the Company’s trust account that held the proceeds from RTPZ’s initial public offering (the “Trust Account”) post-redemption of shares of RTPZ’s Class A common stock from RTPZ’s Class A stockholders. The aggregate cash consideration received was reduced by $95.0 million for the repurchase of common stock and reduced by $43.4 million for the payment of direct transaction costs incurred by Old Hippo and the Company which were reflected as a reduction of proceeds. The remaining consideration consisted of 495,242,606 new ly issued shares of the Company’s common stock. The following table reconciles the elements of the Business Combination and the PIPE investment to the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2021: in millions Recapitalization Cash in trust, net of redemptions $ 37.7 Cash - PIPE 550.0 Less: Cash used for repurchase of common stock (95.0) Less: transaction costs and advisory fees (43.4) Net Cash Received from Business Combination and PIPE Investment $ 449.3 The number of shares of common stock issued immediately following the consummation of the Business Combination and the PIPE Investment: Number of Shares Class A common stock outstanding prior to Business Combination 23,000,000 Less: Redemption of RTPZ Class A common stock (19,261,380) Class A common stock of RTPZ 3,738,620 RTPZ Founder shares – Class B 5,750,000 PIPE Shares 55,000,000 Business Combination and PIPE shares which converted to Hippo common stock 64,488,620 Old Hippo shares, net of repurchase (1) 495,242,606 Total Shares of Common Stock Outstanding Immediately after Business Combination and PIPE Investment 559,731,226 (1) The number of Old Hippo shares was determined based on Old Hippo common stock outstanding immediately prior to the closing of the Business Combination multiplied by the Exchange Ratio of 6.95433 adjusted for buyback of 9,500,000 million shares of common stock. For further details, refer to Note 14, Stockholders’ Equity. In connection with the Business Combination, preferred stock warrants were exercised for cash proceeds of $29.0 million. See also Note 10, Convertible Promissory Notes and Derivative Liability, Note 11, Public Warrants and Private Placement Warrants, Note 13, Convertible Preferred Stock, and Note 14, Stockholders’ Equity for additional information regarding changes to the instruments as a result of the Business Combination. Other Acquisition On August 31, 2021, the Company acquired a software development and engineering consulting firm for the aggregate purchase price of $7.5 million, consisting of cash and equity. The acquisition has been accounted for as a business combination under ASC 805 and was made to further strengthen the Company’s technology and development capabilities. Of the total purchase consideration, $5.0 million has been recorded to goodwill, $0.5 million to acquired intangible assets, and $2.0 million to net working capital. The Company incurred $0.4 million in acquisition related costs which were recognized as general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive income (loss). Included in the arrangement is $5.6 million in equity instruments granted to certain employees that have vesting conditions contingent on certain performance milestones and are accounted for as equity-settled stock-based compensation transactions. These will be recorded as post-combination compensation expense over a service period of up to 18 months, when the performance milestones become probable, if not forfeited by the employees.

Investments

Investments	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investments	3. Investments The amortized cost and fair value of fixed maturities securities and short-term investments are as follows (in millions): September 30, 2021 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Fixed maturities available-for-sale: U.S. government and agencies $ 12.0 $ — $ — $ 12.0 States, and other territories 5.9 — (0.1) 5.8 Corporate securities 18.0 — (0.1) 17.9 Foreign securities 1.2 — — 1.2 Residential mortgage-backed securities 11.7 — (0.1) 11.6 Commercial mortgage-backed securities 5.0 — (0.1) 4.9 Asset backed securities 6.3 — — 6.3 Total fixed maturities available-for-sale 60.1 — (0.4) 59.7 Short-term investments: U.S. government and agencies 12.3 — — 12.3 Total $ 72.4 $ — $ (0.4) $ 72.0 December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Fixed maturities available-for-sale: U.S. government and agencies $ 10.1 $ — $ — $ 10.1 States, and other territories 5.1 — — 5.1 Corporate securities 17.4 — — 17.4 Foreign securities 0.8 — — 0.8 Residential mortgage-backed securities 12.9 — — 12.9 Commercial mortgage-backed securities 5.4 0.1 — 5.5 Asset backed securities 4.2 — — 4.2 Total $ 55.9 $ 0.1 $ — $ 56.0 As of September 30, 2021, no securities have been in a continuous unrealized loss position for greater than 12 months. There were no other-than-temporary impairments recognized for the nine-month periods ended September 30, 2021 and 2020. The amortized cost and fair value of fixed maturities securities by contractual maturity are as follows (in millions): September 30, 2021 Amortized Cost Fair Value Due to mature: One year or less $ 10.6 $ 10.6 After one year through five years 21.8 21.7 After five years 4.6 4.5 After ten years 0.1 0.1 Residential mortgage-backed securities 11.7 11.6 Commercial mortgage-backed securities 5.0 4.9 Asset backed securities 6.3 6.3 Total fixed maturities available-for-sale $ 60.1 $ 59.7 Expected maturities will differ from contractual maturities because issuers may have the right to call or prepay obligations with or without call or prepayment penalties. Net realized gains on fixed maturity securities were insignificant for the periods ended September 30, 2021 and 2020, respectively. The Company’s net investment income is comprised of the following (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Fixed maturities income $ 0.1 $ 0.2 $ 0.3 $ 0.8 Total gross investment income 0.1 0.2 0.3 0.8 Investment expenses — — (0.1) — Net investment income $ 0.1 $ 0.2 $ 0.2 $ 0.8 Pursuant to certain regulatory requirements, the Company is required to hold assets on deposit with various state insurance departments for the benefit of policyholders. These special deposits are included in fixed maturities, available-for-sale on the consolidated balance sheets. The following table reflects special deposits (in millions): September 30, 2021 Amortized Cost Fair Value State New York $ 3.1 $ 3.1 Illinois 1.6 1.6 Colorado 1.5 1.6 Virginia 0.3 0.4 North Carolina 0.3 0.3 New Mexico 0.3 0.3 Vermont 0.3 0.3 Florida 0.3 0.3 Nevada 0.2 0.2 Massachusetts 0.1 0.1 Georgia 0.1 0.1 Total states $ 8.1 $ 8.3

Cash, Cash Equivalents, and Res

Cash, Cash Equivalents, and Restricted Cash	9 Months Ended
	Sep. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, and Restricted Cash	4. Cash, Cash Equivalents, and Restricted Cash The following table sets forth the cash, cash equivalents, and restricted cash (in millions): September 30, December 31, Cash and cash equivalents: Cash $ 183.7 $ 56.7 Money market funds 595.0 372.1 Treasury bills — 23.5 Total cash and cash equivalents 778.7 452.3 Restricted cash: Fiduciary assets 26.0 12.1 Letters of credit and cash on deposit 18.1 28.0 Total restricted cash 44.1 40.1 Total cash, cash equivalents, and restricted cash $ 822.8 $ 492.4

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement	5. Fair Value Measurement The following table summarizes the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis (in millions): September 30, 2021 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 595.0 $ — $ — $ 595.0 Total cash equivalents 595.0 — — 595.0 Fixed maturities available-for-sale: U.S. government and agencies 12.0 — — 12.0 States, and other territories — 5.8 — 5.8 Corporate securities — 17.9 — 17.9 Foreign securities — 1.2 — 1.2 Residential mortgage-backed securities — 11.6 — 11.6 Commercial mortgage-backed securities — 4.9 — 4.9 Asset backed securities — 6.3 — 6.3 Total fixed maturities available-for-sale 12.0 47.7 — 59.7 Short term investments U.S. government and agencies — 12.3 — 12.3 Total financial assets $ 607.0 $ 60.0 $ — $ 667.0 Financial liabilities: Contingent consideration liability $ — $ — $ 11.5 $ 11.5 Public warrants 4.2 — — 4.2 Private placement warrants — — 4.8 4.8 Total financial liabilities $ 4.2 $ — $ 16.3 $ 20.5 December 31, 2020 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 372.1 $ — $ — $ 372.1 Treasury bills 23.5 — — 23.5 Total cash equivalents 395.6 — — 395.6 Fixed maturities available-for-sale: U.S. government and agencies 10.1 — — 10.1 States, and other territories — 5.1 — 5.1 Corporate securities — 17.4 — 17.4 Foreign securities — 0.8 — 0.8 Residential mortgage-backed securities — 12.9 — 12.9 Commercial mortgage-backed securities — 5.5 — 5.5 Asset backed securities — 4.2 — 4.2 Total fixed maturities available-for-sale 10.1 45.9 — 56.0 Total financial assets $ 405.7 $ 45.9 $ — $ 451.6 Financial liabilities: Derivative liability on convertible promissory notes $ — $ — $ 113.3 $ 113.3 Contingent consideration liability — — 12.0 12.0 Preferred stock warrant liabilities — — 22.9 22.9 Total financial liabilities $ — $ — $ 148.2 $ 148.2 The Company’s policy is to recognize transfers into and transfers out of fair value hierarchy levels at the end of each reporting period. During the nine months ended September 30, 2021 and December 31, 2020 there were no transfers between levels in the fair value hierarchy. Preferred Stock Warrant Liabilities The table below presents changes in the preferred stock warrant liability valued using Level 3 inputs (in millions): 2021 2020 Balance as of January 1, $ 22.9 $ 6.7 Changes in fair value 121.6 4.2 Settlement of preferred stock warrants (144.5) $ — Balance as of September 30, $ — $ 10.9 Contingent Consideration The contingent consideration, relating to Old Hippo’s 2019 acquisition of North American Advantage Insurance Services, LLC is re-valued to fair value at the end of each reporting period using the present value of future payments based on an estimate of revenue and customer renewals of the acquiree. There is no limit to the maximum potential contingent consideration as the consideration is based on acquired customer retention. The table below presents the changes in the contingent consideration liability valued using Level 3 inputs (in millions): 2021 2020 Balance as of January 1, $ 12.0 $ 13.8 Payments of contingent consideration (2.6) (4.0) Changes in fair value 2.1 1.9 Balance as of September 30, $ 11.5 $ 11.7 Derivative liability on notes The embedded derivative liabilities on the issued and outstanding convertible promissory notes are re-valued to the current fair value at the end of each reporting period using the income-based approach with or without a 10% discount. As of August 2, 2021, the expected time to conversion used in the final mark to market valuation was 0.0-2.6 years. The table below presents the changes in derivative liability on convertible promissory notes valued using Level 3 inputs (in millions): 2021 Balance as of January 1, $ 113.3 Initial measurement of new derivative 2.8 Changes in fair value 61.4 Settlement of derivative liability (177.5) Balance as of September 30, $ — Warrant liability The Public and Private Placement Warrants (as defined in Note 11 below) were acquired as part of the Business Combination and are measured at fair value on a recurring basis at the end of each reporting period. The Public Warrant Liability associated with the Public Warrants as of September 30, 2021 is classified as a Level 1 fair value measurement due to the use of an observable market quote in an active market, and the Private Placement Warrants are classified within Level 3 of the fair value hierarchy. The Company utilizes a binomial Monte-Carlo simulation to estimate the fair value of the private placement warrants at each reporting period for its warrants that are not actively traded. The estimated fair value of private placement warrant liability is determined using Level 3 inputs. The following table presents the changes in the fair value of the warrant liability (Public Warrants and Private Placement Warrants) (in millions): 2021 Initial measurement, August 2, $ 14.6 Changes in fair value (5.6) Balance as of Balance as of September 30, $ 9.0 The fair value of these private warrants was re-measured based on the following assumptions: September 30, Stock price $ 4.68 Strike price $ 11.50 Risk free rate 1.0 % Volatility 54.0 % Remaining term (years) 4.84

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets September 30, 2021 December 31, 2020 Weighted- Average Useful Life Remaining (in years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (in millions) (in millions) Agency and carrier relationships 7.7 $ 13.5 $ (1.3) $ 12.2 $ 13.5 $ (0.1) $ 13.4 State licenses and domain name Indefinite 10.5 — 10.5 7.1 — 7.1 Customer relationships 3.8 13.3 (5.4) 7.9 13.2 (3.8) 9.4 Developed technology 1.3 3.6 (2.3) 1.3 3.6 (1.4) 2.2 VOBA 1.2 0.1 (0.1) — 0.1 — 0.1 Other 5.9 2.3 (0.5) 1.8 1.9 (0.2) 1.7 Total intangible assets, net $ 43.3 $ (9.6) $ 33.7 $ 39.4 $ (5.5) $ 33.9 Amortization expense related to intangible assets for the three and nine months ended September 30, 2021 was $1.3 million and $4.1 million, respectively, and for the three and nine months ended September 30, 2020 was $0.9 million and $2.7 million, respectively. The amortization expense is included in technology and development expenses for developed technology, sales and marketing expenses for customer relationships, agency relationships, carrier relationships and other. Amortization expense related to value of business acquired (VOBA) is included in general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	7. Accrued Expenses and Other Liabilities September 30, December 31, (in millions) Accrued wages and commissions $ 6.7 $ 5.0 Deferred revenue 8.5 1.7 Advances from customers 9.1 4.4 Accrued licenses and taxes 7.8 2.5 Accrued transaction cost 2.3 — Warrant liability 9.0 — Other 18.5 12.1 Total accrued expenses and other liabilities $ 61.9 $ 25.7

Loss and Loss Adjustment Expens

Loss and Loss Adjustment Expense Reserves	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Loss and Loss Adjustment Expense Reserves	8. Loss and Loss Adjustment Expense Reserves The reconciliation of the beginning and ending reserve balances for losses and loss adjustment expenses, net of reinsurance is summarized as follows for the nine months ended September 30, (in millions): 2021 2020 Reserve for losses and LAE gross of reinsurance recoverables on unpaid losses and LAE as of beginning of the period $ 105.1 $ — Reinsurance recoverables on unpaid losses (92.1) — Reserve for losses and LAE, net of reinsurance recoverables as of beginning of the period 13.0 — Add: Incurred losses and LAE, net of reinsurance, related to: Current year 65.6 13.9 Prior years (0.6) — Total incurred 65.0 13.9 Deduct: Loss and LAE payments, net of reinsurance, related to: Current year 33.5 7.9 Prior year 6.8 — Total paid 40.3 7.9 Reserve for losses and LAE, net of reinsurance recoverables acquired from Spinnaker — 5.0 Reserve for losses and LAE, net of reinsurance recoverables at end of period 37.7 11.0 Add: Reinsurance recoverables on unpaid losses and LAE at end of period 202.0 113.5 Reserve for losses and LAE gross of reinsurance recoverables on unpaid losses and LAE as of end of the period $ 239.7 $ 124.5 Loss development occurs when actual losses incurred vary from the Company’s previously developed estimates, which are established through our reserve analysis processes. Net incurred losses and LAE experienced favorable development of $0.6 million and $0 million for the nine months ended September 30, 2021 and 2020, respectively. The prior period net reserve release of $0.6 million was driven by favorable loss development. These changes are generally a result of ongoing analysis of recent loss development trends. Loss and LAE are updated as additional information becomes known. Unpaid loss and LAE includes anticipated salvage and subrogation recoverable. The amount of anticipated salvage and subrogation recoverable is insignificant as of September 30, 2021.

Reinsurance

Reinsurance	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Reinsurance	9. Reinsurance The Company’s insurance company subsidiaries have entered into quota share and excess of loss reinsurance contracts, under which the insurance company subsidiaries have ceded some, but not all of, the liabilities to third party reinsurers including, but not limited to, catastrophe exposure. Additionally, the reinsurance contracts may be subject to contingent commission adjustments and loss corridor provisions. The Company is not relieved of its primary obligations to policyholders in the event of a default or the insolvency of its reinsurers; therefore, a credit exposure exists to the extent that any reinsurer fails to meet its obligations in the reinsurance agreements. To mitigate this exposure to reinsurance insolvencies, the Company evaluates the financial condition of its reinsurers and, in certain circumstances, holds substantial collateral (in the form of letters of credit, trusts, and funds withheld) as security under the reinsurance agreements. No amounts have been recorded in the three and nine months ended September 30, 2021 and 2020 for amounts anticipated to be uncollectible or for the anticipated failure of a reinsurer to meet its obligations under the contracts. For its primary reinsurance treaty incepting in 2021, the Company’s insurance subsidiaries secured quota share reinsurance from a diverse panel of nine third-party reinsurers with A.M. Best ratings of A- or better. A total of approximately 11% of the risk was retained either by Spinnaker or RHS, which aligns interests with third-party reinsurers. Two of the reinsurers, representing approximately one-third of the programs, provided three-year agreements. The following tables reflect amounts affecting the statements of operations and comprehensive loss for ceded reinsurance for the three and nine months ended September 30, 2021 and 2020 (in millions): For the Three Months Ended September 30, 2021 2020 Written premiums Earned premiums Loss and LAE incurred Written premiums Earned premiums Loss and LAE incurred Direct $ 129.0 $ 98.9 $ 125.4 $ 22.4 $ 21.1 $ 32.0 Assumed — 2.3 4.6 6.5 3.1 5.4 Gross 129.0 101.2 130.0 28.9 24.2 37.4 Ceded (123.1) (90.3) (103.7) (19.0) (19.5) (28.7) Net $ 5.9 $ 10.9 $ 26.3 $ 9.9 $ 4.7 $ 8.7 For the Nine Months Ended September 30, 2021 2020 Written premiums Earned premiums Loss and LAE incurred Written premiums Earned premiums Loss and LAE incurred Direct $ 353.4 $ 253.8 $ 401.5 $ 22.4 $ 21.1 $ 32.0 Assumed 3.3 8.9 14.7 21.1 7.9 10.6 Gross 356.7 262.7 416.2 43.5 29.0 42.6 Ceded (331.5) (232.8) (351.2) (21.0) (20.3) (28.7) Net $ 25.2 $ 29.9 $ 65.0 $ 22.5 $ 8.7 $ 13.9

Convertible Promissory Notes an

Convertible Promissory Notes and Derivative Liability	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Promissory Notes and Derivative Liability	10. Convertible Promissory Notes and Derivative Liability In November 2020, December 2020, and February 2021, Old Hippo issued convertible promissory notes totaling $384.5 million that mature in November 2023, December 2023, and February 2024. The convertible promissory notes bear interest at 2.5% compounded semi-annually. If conversion event has not occurred, this annual interest rate will automatically increase by 2.5% up to 7.5% after certain periods specified in the Purchase Agreement. After 15 months from issuance, if a conversion event has not occurred, interest shall accrue at 5% per annum, compounding semi-annually, unless the Company has filed an S-1 or signed a letter of intent or definitive agreements with respect to a qualified private round or public issuer merger, in which case the interest rate increase to 5% shall apply after 21 months from issuance, provided a conversion on event has not occurred. With a prior written consent from the investor, the Company may repay the convertible promissory notes and interest, in whole or in part, any time in cash before the maturity date without a prepayment penalty. The convertible promissory notes contain an embedded derivative. The fair value of the embedded derivatives upon issuance of the notes was $110.0 million. Interest expense is accreted on the convertible promissory notes between issuance and maturity dates with the expectation that principal and interest are likely to be settled in shares of common stock of the Company at a variable conversion price calculated at 90% of the price of the common stock of the Company. For additional information on derivative liability, refer to Note 5, Fair Value Measurement of these interim consolidated financial statements. In connection with the Closing of the Business Combination on August 2, 2021, the convertible promissory notes converted into 43,449,312 shares of the Company common stock. The carrying value of the convertible promissory notes at the conversion date of $302.3 million, net of $86.9 million of the deferred discount and issuance costs, and the carrying value of the derivative liability of $177.5 million after the final fair value adjustment on the conversion date were recorded to equity. A gain of $47.0 million was recognized upon the extinguishment of the debt and related derivative liability.

Public Warrants and Private Pla

Public Warrants and Private Placement Warrants	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Public Warrants and Private Placement Warrants	11. Public Warrants and Private Placement Warrants In November 2020, in connection with the RTPZ IPO, RTPZ issued 4,600,000 warrants (the “Public Warrants”) to purchase its Class A ordinary shares at $11.50 per share. Concurrently, RTPZ also issued 4,400,000 warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Public and Private Placement Warrants”) to its Sponsor to purchase its Class A ordinary shares at $11.50 per share. In connection with the Business Combination, the Public and Private Placement warrants converted, on a one-for-one basis into warrants to purchase Company common stock. All of the Public and Private Placement Warrants were outstanding as of September 30, 2021. The Company classified the Public and Private Placement Warrants as liabilities on its consolidated balance sheets as these instruments are precluded from being indexed to our own stock given the terms allow for a settlement adjustment that does not meet the scope of the fixed-for-fixed exception in Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging. In certain events outside of our control, the Public Warrant and Private Placement Warrant holders are entitled to receive cash, while in certain scenarios, the holders of the common stock are not entitled to receive cash or may receive less than 100% of any proceeds in cash, which precludes these instruments from being classified within equity pursuant to ASC 815-40. The Public and Private Placement Warrants were initially recorded at fair value on the date of the Business Combination and are subsequently adjusted to fair value at each subsequent reporting date. Changes in the fair value of these instruments are recognized within interest and other (income) expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss. See Note 5, Fair Value Measurement for additional information on valuation.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Operating Leases The Company leases office space under non-cancelable operating leases with various expiration dates through 2029. Rent expense, which is recognized on a straight-line basis over the lease term, for the three and nine months ended September 30, 2021, was $0.8 million and $2.2 million, respectively, and for the three and nine months ended September 30, 2020 was $0.7 million and $2.1 million, respectively. During the three months ended September 30, 2021, the Company extended a current lease and leased additional square footage in Texas for future payments of approximately $8.0 million extending through 2026. Litigation The Company is subject to claims and legal proceedings that arise in the normal course of business. Accruals for these items have been provided to the extent that losses are deemed probable and are estimable. The Company’s insurance subsidiaries are, from time to time, subject to a variety of regulatory audits or actions relating to current and past business operations and practices. The Company does not believe any pending regulatory matters will have a material adverse effect on the Company’s consolidated financial condition, results of operations, or cash flows.

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	13. Convertible Preferred Stock Prior to September 30, 2020, Old Hippo issued Series A-1, A-2, B, C, D, and E convertible preferred stock. There were no new issuances of preferred stock during the nine month period ended September 30, 2021, other than the exercise of preferred stock warrants noted below. December 31, 2020 Issuance Price Per Share Authorized Shares Shares Issued and Outstanding Net Carrying Value Liquidation Preference Preferred A-1 Stock $ 0.56965 40,959,815 40,959,815 $ 3.4 $ 3.4 Preferred A-2 Stock 1.57432 48,790,097 48,590,772 10.9 11.0 Preferred B Stock 3.59757 48,326,627 48,326,627 24.9 25.0 Preferred C Stock 7.04471 69,101,902 69,101,895 56.1 70.0 Preferred C-1 Stock 11.74119 17,145,581 — — — Preferred D Stock 15.16420 45,860,183 45,860,183 99.8 100.0 Preferred E Stock 19.66420 53,048,255 53,048,151 149.7 150.0 Total 323,232,460 305,887,443 $ 344.8 $ 359.4 Upon the Closing of the Business Combination, after the exercise of preferred stock warrants, all outstanding shares of Old Hippo’s preferred stock automatically converted into 323,232,349 shares of the Company’s common stock after giving effect to the Exchange Ratio. See Note 2, Business Combinations for additional information on the Business Combination. Preferred Stock Warrant Liabilities In connection with obtaining a line of credit in March 2017, Old Hippo issued 28,662 warrants to purchase Series A-2 Preferred Stock. The warrants vested immediately and were exercisable up to March 13, 2027. In connection with the issuance of Series C Preferred Stock, in October 2018, Old Hippo issued to an investor 2,465,454 warrants to purchase Series C-1 Preferred Stock. The warrants are exercisable upon vesting. In April 2020, the warrants were fully vested. The warrants will expire at the earliest of a deemed liquidation event, stock sale, or October 25, 2022. The preferred stock warrant liability is remeasured at each reporting period end with changes in fair value upon remeasurement being recorded within interest and other (income) expense in the consolidated statements of operations and comprehensive loss. See Note 5, Fair Value Measurement for additional information on the fair value of preferred stock warrant liability. In August 2021, prior to the Business Combination, the holders exercised their warrants for 2,494,116 shares of Old Hippo preferred stock. After giving effect to the Exchange Ratio upon the Closing of the Business Combination, the 2,494,116 shares of Old Hippo preferred stock converted into 17,344,906 shares of the Company’s common stock. The Company used the fair value of its common share per the Business Combination to mark to market the value the warrants upon exercise immediately prior to the Business Combination.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity	14. Stockholders’ Equity Common Stock On August 2, 2021, the Company’s common stock and warrants began trading on the New York Stock Exchange (“NYSE”) under the ticker symbols “HIPO” and “HIPO.W”, respectively. Pursuant to Certificate of Incorporation, the Company is authorized to issue 2 billion shares of common stock, with a par value of $0.0001 per share. As described in Note 2, Business Combinations, the Company issued 495,242,606 shares of the Company’s common stock in the Business Combination. The below table shows the conversion of Old Hippo’s outstanding instruments on the date of the Closing that were converted, exercised, or issued as stock consideration. Description Balance outstanding prior to the Business Combination Exchange Ratio Post Conversion Balances Old Hippo common stock 15,940,914 6.95433 110,858,374 Old Hippo convertible preferred stock 43,985,178 6.95433 305,887,443 Old Hippo convertible promissory notes 6,247,807 6.95433 43,449,312 Old Hippo preferred stock warrants 2,494,116 6.95433 17,344,906 Old Hippo common stock warrants 3,911,610 6.95433 27,202,571 504,742,606 Less: Repurchase of common stock (9,500,000) Net Old Hippo shares consideration 495,242,606 In connection with the Closing of the Business Combination on August 2, 2021, the Company issued 55,000,000 shares of Common Stock in the PIPE Investment to certain qualified institutional buyers and accredited investors that agreed to purchase such shares, for aggregate consideration of $550 million. Common Stock Warrants On August 2, 2021, 3,911,610 warrants were exercised for shares of Old Hippo common stock and, after giving effect to the Exchange Ratio and upon the Closing of the Business Combination, converted into 27,202,571 shares of Hippo Holdings Inc. common stock. Stock-Based Compensation Plans 2019 Stock Option and Grant Plan Adopted in 2019, the 2019 Stock Option and Grant Plan (“the 2019 Stock Plan”) provides for the direct award or sale of shares, the grant of options to purchase shares, and the grant of restricted stock units (“RSUs”) to employees, consultants, and outside directors of the Company. Stock options under the plan may be either incentive stock options (“ISOs”) or non-qualified stock options (“NSOs”), with an exercise price of not less than 100% of fair market value on the grant date, with a term less than or equal to ten years. The vesting period of each option and RSU shall be as determined by a committee of the Company’s board of directors but is generally over four years. Upon the closing of the Business Combination, the remaining unallocated share reserve under the 2019 Plan was cancelled and no new awards will be granted under such plan. Awards outstanding under the 2019 Plan were assumed by the Company upon the Closing and continue to be governed by the terms of the 2019 Plan. 2021 Incentive Award Plan In connection with the Closing of the Business Combination, on August 2, 2021, the Company adopted the 2021 Incentive Award Plan (the “2021 Plan”), which authorized for issuance 78,000,000 shares of common stock. The 2021 Plan provides for the issuance of a variety of stock-based compensation awards, including stock options, stock appreciation rights (“SARs”), restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents, or other stock or cash-based awards. The vesting period of each option and award shall be as determined by a committee of the Company’s board of directors but is generally over four years. Stock Options The following table summarizes option activity under the plans: Options Outstanding Weighted-Average Remaining Aggregate Intrinsic Value Number of Shares Weighted Average Exercise Price Contract Term Outstanding as of January 1, 2021 72,205,242 $ 0.70 8.90 $ 108.9 Granted 8,845,569 4.88 Exercised (20,728,860) 0.30 Cancelled/Expired (6,954,384) 0.90 Outstanding as of September 30, 2021 53,367,567 $ 1.52 8.58 $ 178.7 Vested and exercisable as of September 30, 2021 12,945,529 $ 0.69 7.97 $ 51.7 The aggregate intrinsic value of options exercised during the nine months ended September 30, 2021 and 2020 was $35.7 million and $3.5 million, respectively, and is calculated based on the difference between the exercise price and the fair value of the Company’s common stock as of the exercise date. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2021 and 2020 was $2.24 and $1.97 per share, respectively. Total unrecognized compensation cost of $37.5 million as of September 30, 2021 is expected to be recognized over a weighted-average period of 2.6 years. Valuation Assumptions of Stock Options The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes-Merton option-pricing model, based on the following inputs: September 30, December 31, Expected term (in years) 5.4 - 6.1 5.6 - 6.1 Expected volatility 29.7% - 30.1% 22.6% - 29.9% Risk-free interest rate 0.6% - 1.0% 0.3% - 1.6% Expected dividend yield — % — % Each of th ese inputs is subjective and generally requires significant judgment to determine. Expected Term – The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company has opted to use the simplified method for estimating the expected term of options. Accordingly, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). Expected Volatility – Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of peer companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate – The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the grant’s expected term. Expected Dividend Yield – The Company has never paid dividends and does not currently expect to pay dividends. Fair value of common stock – Prior to contemplating a public market transaction, the Company established the fair value of common stock by using the option pricing model (Black-Scholes Model based) via the back-solve method and through placing weight on previously redeemable preferred stock transactions. On ce the Company made intentional progress toward pursuing a public market transaction, it began applying the probability-weighted expected return method to determine the fair value of its common stock. The probability weightings assigned to certain potential exit scenarios were based on management’s expected near-term and long-term funding requirements and assessment of the most attractive liquidation possibilities at the time of the valuation. Subsequent to the Business Combination, the Company determined the value of its common stock based on the observable daily closing price of its common stock (ticker symbol “HIPO”). Early Exercises of Stock Options In 2019, certain employees early exercised stock options in exchange for promissory notes. Old Hippo accounted for the promissory notes as nonrecourse in their entirety because the promissory notes are not aligned with a corresponding percentage of the underlying shares. The early exercises of options were not deemed to be substantive exercises for accounting purposes. Each of these loans and all interest accrued thereon was forgiven upon the consummation of the Business Combination. The foregiveness of the promissory notes were deemed to be exercises of the 9.4 million stock options with an intrinsic value of $94.0 million on the date of foregiveness. The Company accounted for the forgiveness as a modification to the options granted and incurred an incremental stock-based compensation charge of $2.1 million during the quarter. The related number of unvested shares subject to repurchase as of September 30, 2021 was 3,534,296. In 2020 and 2021, certain employees early exercised stock option with cash. On September 30, 2021 and December 31, 2020, the Company had $2.4 million and $2.5 million, respectively, recorded in accrued expenses and other liabilities related to early exercises of the stock options, and the related number of unvested shares subject to repurchase was 2,231,896 and 2,399,245, respectively. Total stock-based compensation expense, classified in the accompanying consolidated statements of operations and comprehensive loss was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Losses and loss adjustment expenses $ 0.1 $ — $ 0.2 $ — Insurance related expenses — 0.1 0.2 0.2 Technology and development 0.8 1.8 1.7 2.3 Sales and marketing 0.9 0.5 3.1 0.8 General and administrative 2.7 10.8 4.6 11.7 Total stock-based compensation expense $ 4.5 $ 13.2 $ 9.8 $ 15.0 Restricted Stock Units In August 2021, the Company granted RSUs under the 2021 Incentive Award Plan. The RSUs granted to employees are measured based on the grant-date fair value. In general, our RSUs vest over a service period of four years. Stock-based compensation expense is recognized based on the straight-line basis over the requisite service period. We account for forfeitures as they occur. As of September 30, 2021, 210,526 RSUs have been granted with a weighted-average grant date fair value of $5.28, all of which were unvested at period end. Total unrecognized compensation cost related to unvested RSUs is $1.0 million as of September 30, 2021, and it is expected to be recognized over a weighted-average period of 3.9 years. Performance Restricted Stock Units In August 2021, the Company granted performance-based restricted stock units ( PRSUs), w hich become eligible to vest subject to the achievement of specified performance conditions over the next 18-months. Compensation expense for PRSUs reflects the estimated probability that performance conditions at target or above will be met. As of September 30, 2021, 1,269,388 PSRUs have been granted with a weighted-average grant date fair value of $5.28, all of which were unvested at period end. Total unrecognized compensation cost related to unvested PRSUs is $6.7 million as of September 30, 2021, and it is expected to be recognized over the next 18 months if the awards become probable of vesting. 2021 Employee Stock Purchase Plan In connection with the closing of the Business Combination, the Company adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which authorized 13,000,000 shares of common stock for issuance. The 2021 ESPP is designed to allow eligible employees of the Company to purchase shares of our common stock with their accumulated payroll deductions. As of September 30, 2021, this plan has not yet been rolled out to Company employees.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes The consolidated effective tax rate was (0.1)% and 2.1% for the nine months ended September 30, 2021 and 2020, respectively. The difference between the rate for the nine months ended September 30, 2021 and the U.S. federal income tax rate of 21% was due primarily to a full valuation allowance against the Company’s net deferred tax assets. The difference between the rate for the nine months ended September 30, 2020 and the U.S. federal income tax rate of 21% was due primarily to a full valuation allowance against the Company’s net deferred tax assets, partially offset by a reduction in the valuation allowance as a result of the acquisition of Spinnaker. The Company did not have an unrecognized tax benefit as of September 30, 2021 and 2020. No interest or penalties were incurred during the nine months ended September 30, 2021 and 2020.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	16. Net Loss Per Share Attributable to Common Stockholders Net loss per share attributable to common stockholders was computed as follows: Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Numerator: Net loss attributable to Hippo – basic and diluted (in millions) $ (30.9) $ (38.6) $ (310.7) $ (87.4) Denominator: Weighted-average shares used in computing net loss per share attributable to Hippo — basic and diluted 386,882,408 87,383,796 175,690,513 85,864,640 Net loss per share attributable to Hippo — basic and diluted $ (0.08) $ (0.44) $ (1.77) $ (1.02) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive are as follows: September 30, 2021 2020 Convertible preferred stock (on an as if converted basis) — 264,641,887 Outstanding options 64,131,579 56,222,150 Warrants to purchase common shares 1,978,022 32,949,982 Warrants to purchase preferred shares — 17,344,912 Common stock subject to repurchase 10,584,764 9,461,880 RSU and PRSUs 23,906 — Total 76,718,271 380,620,811

Geographical Breakdown of Gross

Geographical Breakdown of Gross Written Premium	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Geographical Breakdown of Gross Written Premium	17. Geographical Breakdown of Gross Written Premium Gross written premium (“GWP”) by state is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Amount % of GWP Amount % of GWP Amount % of GWP Amount % of GWP State Texas $ 31.5 24.4 % $ 10.5 36.3 % $ 104.5 29.3 % $ 21.4 49.2 % California 22.6 17.5 % 3.7 12.8 % 64.3 18.0 % 3.7 8.5 % Florida 6.5 5.0 % 1.4 4.8 % 20.9 5.9 % 1.4 3.2 % Georgia 6.2 4.8 % 1.0 3.5 % 16.0 4.5 % 1.4 3.2 % Illinois 6.5 5.0 % 1.3 4.5 % 14.1 4.0 % 2.0 4.6 % Missouri 3.8 2.9 % 1.0 3.5 % 9.7 2.7 % 1.4 3.2 % Colorado 3.8 2.9 % 0.4 1.4 % 9.5 2.7 % 0.4 0.9 % Arizona 3.2 2.5 % 0.4 1.4 % 8.5 2.4 % 0.4 0.9 % New Jersey 2.8 2.2 % 0.7 2.4 % 7.4 2.1 % 0.7 1.6 % Ohio 3.0 2.3 % 1.0 3.5 % 7.9 2.2 % 1.5 3.4 % Other 39.1 30.3 % 7.5 26.0 % 93.9 26.3 % 9.2 21.1 % Total $ 129.0 100 % $ 28.9 100 % $ 356.7 100 % $ 43.5 100 %

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Consolidation	The interim condensed consolidated financial statements are presented in accordance with Generally Accepted Accounting Principles (“GAAP”) and include the Company’s consolidated subsidiaries. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements and accompanying footnotes should be read in conjunction with the audited consolidated financial statements of RTPZ and Old Hippo as of and for the year ended December 31, 2020 presented in the Company’s Registration Statement on Form S-1 (File No. 333-259040) filed with the SEC on August 24, 2021. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company’s significant accounting policies, compared to the accounting policies described in Note 1, Description of Business and Summary of Significant Accounting Policies, in the Notes to Old Hippo’s Consolidated Financial Statements as of and for for the year ended December 31, 2020 presented in the Company’s Registration Statement on Form S-1 (File No. 333-259040) filed with the SEC on August 24, 2021. As a result of the Business Combination, which was completed on August 2, 2021, prior period share and per share amounts presented in the accompanying Unaudited Condensed Consolidated Financial Statements and these related notes have been converted in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. Refer to Note 2 for additional information. All intercompany transactions have been eliminated in consolidation. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. The interim financial information is unaudited, but reflects all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. Interim results are not necessarily indicative of the results for a full year.
Use of Estimates	The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include, but are not limited to, loss and loss adjustment expense (“LAE”) reserves, provision for commission slide and cancellations, reinsurance recoverable on unpaid losses and LAE, the fair values of investments, common stock, stock-based awards, warrant liabilities, contingent consideration liabilities, embedded derivative liabilities, acquired intangible assets and goodwill, deferred tax assets and uncertain tax positions, and revenue recognition. The Company evaluates these estimates on an ongoing basis. These estimates are informed by experience and other assumptions that the Company believes are reasonable under the circumstances. Actual results may differ significantly from these estimates.
Business Combination	The Company accounts for acquisitions of entities or asset groups that qualify as businesses using the acquisition method of accounting in accordance with ASC 805, Business Combinations. Purchase consideration is allocated to the tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date, which are measured in accordance with the principles outlined in ASC 820, Fair Value Measurement. The determination of fair value requires management to make estimates about discount rates, future expected cash flows, market conditions and other future events that are highly subjective in nature. The excess of the total purchase consideration over the fair value of the identified net assets acquired is recognized as goodwill. The results of the acquired businesses are included in the results of operations beginning from the date of acquisition. Acquisition-related costs are expensed as incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the allocation of purchase consideration and to the fair values of assets acquired and liabilities assumed to the extent that additional information becomes available. After this period, any subsequent adjustments are recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss). The Business Combination on August 2, 2021 was accounted for as a reverse recapitalization. See Note 2 for additional information.
Emerging Growth Company	The Company currently qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 and is provided the option to adopt new or revised accounting guidance either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. The Company has elected to adopt new or revised accounting guidance within the same time period as private companies, unless, indicated below, management determines it is preferable to take advantage of early adoption provisions offered within the applicable guidance.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted Internal-Use Software In August 2018, the FASB issued ASU No. 2018-15, Intangibles — Goodwill and Other — Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract . The intent of this pronouncement is to align the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software as defined in ASC 350-40. ASU 2018-15 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted this new guidance on a prospective basis on January 1, 2021. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) . Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of future lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). This ASU is effective for annual reporting periods beginning after December 15, 2021, and interim reporting periods beginning after December 15, 2022. Under this guidance, we will record assets and liabilities relating primarily to our long-term office leases. The Company currently is computing the impact of Topic 842 on our consolidated financial statements and do not expect to have a material impact on the Company’s consolidated statements of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), and subsequent related ASUs, which amends the guidance on the impairment of financial instruments by requiring measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for fiscal years, and for interim periods within the fiscal years, beginning after December 15, 2022. The Company is currently evaluating the impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. This ASU will be effective for annual periods beginning after December 15, 2020, and interim periods beginning after December 15, 2020. ASU 2019-12 will be effective for private entities for annual periods beginning after December 15, 2021, and interim periods beginning after December 15, 2022, with early adoption permitted. The Company expects to adopt ASU 2019-12 under the private company transition guidance beginning January 1, 2022 and does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the timing of adoption and the impact on the consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule Of Reverse Recapitalization	The following table reconciles the elements of the Business Combination and the PIPE investment to the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2021: in millions Recapitalization Cash in trust, net of redemptions $ 37.7 Cash - PIPE 550.0 Less: Cash used for repurchase of common stock (95.0) Less: transaction costs and advisory fees (43.4) Net Cash Received from Business Combination and PIPE Investment $ 449.3 The number of shares of common stock issued immediately following the consummation of the Business Combination and the PIPE Investment: Number of Shares Class A common stock outstanding prior to Business Combination 23,000,000 Less: Redemption of RTPZ Class A common stock (19,261,380) Class A common stock of RTPZ 3,738,620 RTPZ Founder shares – Class B 5,750,000 PIPE Shares 55,000,000 Business Combination and PIPE shares which converted to Hippo common stock 64,488,620 Old Hippo shares, net of repurchase (1) 495,242,606 Total Shares of Common Stock Outstanding Immediately after Business Combination and PIPE Investment 559,731,226 (1) The number of Old Hippo shares was determined based on Old Hippo common stock outstanding immediately prior to the closing of the Business Combination multiplied by the Exchange Ratio of 6.95433 adjusted for buyback of 9,500,000 million shares of common stock. For further details, refer to Note 14, Stockholders’ Equity.

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Fixed Maturities Securities and Short-Term Investments	The amortized cost and fair value of fixed maturities securities and short-term investments are as follows (in millions): September 30, 2021 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Fixed maturities available-for-sale: U.S. government and agencies $ 12.0 $ — $ — $ 12.0 States, and other territories 5.9 — (0.1) 5.8 Corporate securities 18.0 — (0.1) 17.9 Foreign securities 1.2 — — 1.2 Residential mortgage-backed securities 11.7 — (0.1) 11.6 Commercial mortgage-backed securities 5.0 — (0.1) 4.9 Asset backed securities 6.3 — — 6.3 Total fixed maturities available-for-sale 60.1 — (0.4) 59.7 Short-term investments: U.S. government and agencies 12.3 — — 12.3 Total $ 72.4 $ — $ (0.4) $ 72.0 December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Fixed maturities available-for-sale: U.S. government and agencies $ 10.1 $ — $ — $ 10.1 States, and other territories 5.1 — — 5.1 Corporate securities 17.4 — — 17.4 Foreign securities 0.8 — — 0.8 Residential mortgage-backed securities 12.9 — — 12.9 Commercial mortgage-backed securities 5.4 0.1 — 5.5 Asset backed securities 4.2 — — 4.2 Total $ 55.9 $ 0.1 $ — $ 56.0
Investments Classified by Contractual Maturity Date	The amortized cost and fair value of fixed maturities securities by contractual maturity are as follows (in millions): September 30, 2021 Amortized Cost Fair Value Due to mature: One year or less $ 10.6 $ 10.6 After one year through five years 21.8 21.7 After five years 4.6 4.5 After ten years 0.1 0.1 Residential mortgage-backed securities 11.7 11.6 Commercial mortgage-backed securities 5.0 4.9 Asset backed securities 6.3 6.3 Total fixed maturities available-for-sale $ 60.1 $ 59.7
Investment Income	The Company’s net investment income is comprised of the following (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Fixed maturities income $ 0.1 $ 0.2 $ 0.3 $ 0.8 Total gross investment income 0.1 0.2 0.3 0.8 Investment expenses — — (0.1) — Net investment income $ 0.1 $ 0.2 $ 0.2 $ 0.8
Special Deposits	The following table reflects special deposits (in millions): September 30, 2021 Amortized Cost Fair Value State New York $ 3.1 $ 3.1 Illinois 1.6 1.6 Colorado 1.5 1.6 Virginia 0.3 0.4 North Carolina 0.3 0.3 New Mexico 0.3 0.3 Vermont 0.3 0.3 Florida 0.3 0.3 Nevada 0.2 0.2 Massachusetts 0.1 0.1 Georgia 0.1 0.1 Total states $ 8.1 $ 8.3

Cash, Cash Equivalents, and R_2

Cash, Cash Equivalents, and Restricted Cash (Tables)	9 Months Ended
	Sep. 30, 2021
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	The following table sets forth the cash, cash equivalents, and restricted cash (in millions): September 30, December 31, Cash and cash equivalents: Cash $ 183.7 $ 56.7 Money market funds 595.0 372.1 Treasury bills — 23.5 Total cash and cash equivalents 778.7 452.3 Restricted cash: Fiduciary assets 26.0 12.1 Letters of credit and cash on deposit 18.1 28.0 Total restricted cash 44.1 40.1 Total cash, cash equivalents, and restricted cash $ 822.8 $ 492.4
Restrictions on Cash and Cash Equivalents	The following table sets forth the cash, cash equivalents, and restricted cash (in millions): September 30, December 31, Cash and cash equivalents: Cash $ 183.7 $ 56.7 Money market funds 595.0 372.1 Treasury bills — 23.5 Total cash and cash equivalents 778.7 452.3 Restricted cash: Fiduciary assets 26.0 12.1 Letters of credit and cash on deposit 18.1 28.0 Total restricted cash 44.1 40.1 Total cash, cash equivalents, and restricted cash $ 822.8 $ 492.4

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The following table summarizes the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis (in millions): September 30, 2021 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 595.0 $ — $ — $ 595.0 Total cash equivalents 595.0 — — 595.0 Fixed maturities available-for-sale: U.S. government and agencies 12.0 — — 12.0 States, and other territories — 5.8 — 5.8 Corporate securities — 17.9 — 17.9 Foreign securities — 1.2 — 1.2 Residential mortgage-backed securities — 11.6 — 11.6 Commercial mortgage-backed securities — 4.9 — 4.9 Asset backed securities — 6.3 — 6.3 Total fixed maturities available-for-sale 12.0 47.7 — 59.7 Short term investments U.S. government and agencies — 12.3 — 12.3 Total financial assets $ 607.0 $ 60.0 $ — $ 667.0 Financial liabilities: Contingent consideration liability $ — $ — $ 11.5 $ 11.5 Public warrants 4.2 — — 4.2 Private placement warrants — — 4.8 4.8 Total financial liabilities $ 4.2 $ — $ 16.3 $ 20.5 December 31, 2020 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 372.1 $ — $ — $ 372.1 Treasury bills 23.5 — — 23.5 Total cash equivalents 395.6 — — 395.6 Fixed maturities available-for-sale: U.S. government and agencies 10.1 — — 10.1 States, and other territories — 5.1 — 5.1 Corporate securities — 17.4 — 17.4 Foreign securities — 0.8 — 0.8 Residential mortgage-backed securities — 12.9 — 12.9 Commercial mortgage-backed securities — 5.5 — 5.5 Asset backed securities — 4.2 — 4.2 Total fixed maturities available-for-sale 10.1 45.9 — 56.0 Total financial assets $ 405.7 $ 45.9 $ — $ 451.6 Financial liabilities: Derivative liability on convertible promissory notes $ — $ — $ 113.3 $ 113.3 Contingent consideration liability — — 12.0 12.0 Preferred stock warrant liabilities — — 22.9 22.9 Total financial liabilities $ — $ — $ 148.2 $ 148.2
Liabilities Measured on at Fair Value, Unobservable Input Reconciliation	The table below presents changes in the preferred stock warrant liability valued using Level 3 inputs (in millions): 2021 2020 Balance as of January 1, $ 22.9 $ 6.7 Changes in fair value 121.6 4.2 Settlement of preferred stock warrants (144.5) $ — Balance as of September 30, $ — $ 10.9 2021 2020 Balance as of January 1, $ 12.0 $ 13.8 Payments of contingent consideration (2.6) (4.0) Changes in fair value 2.1 1.9 Balance as of September 30, $ 11.5 $ 11.7 2021 Balance as of January 1, $ 113.3 Initial measurement of new derivative 2.8 Changes in fair value 61.4 Settlement of derivative liability (177.5) Balance as of September 30, $ — The following table presents the changes in the fair value of the warrant liability (Public Warrants and Private Placement Warrants) (in millions): 2021 Initial measurement, August 2, $ 14.6 Changes in fair value (5.6) Balance as of Balance as of September 30, $ 9.0
Fair Value Measurement Inputs and Valuation Techniques	The fair value of these private warrants was re-measured based on the following assumptions: September 30, Stock price $ 4.68 Strike price $ 11.50 Risk free rate 1.0 % Volatility 54.0 % Remaining term (years) 4.84

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	September 30, 2021 December 31, 2020 Weighted- Average Useful Life Remaining (in years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (in millions) (in millions) Agency and carrier relationships 7.7 $ 13.5 $ (1.3) $ 12.2 $ 13.5 $ (0.1) $ 13.4 State licenses and domain name Indefinite 10.5 — 10.5 7.1 — 7.1 Customer relationships 3.8 13.3 (5.4) 7.9 13.2 (3.8) 9.4 Developed technology 1.3 3.6 (2.3) 1.3 3.6 (1.4) 2.2 VOBA 1.2 0.1 (0.1) — 0.1 — 0.1 Other 5.9 2.3 (0.5) 1.8 1.9 (0.2) 1.7 Total intangible assets, net $ 43.3 $ (9.6) $ 33.7 $ 39.4 $ (5.5) $ 33.9
Schedule of Finite-Lived Intangible Assets	September 30, 2021 December 31, 2020 Weighted- Average Useful Life Remaining (in years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (in millions) (in millions) Agency and carrier relationships 7.7 $ 13.5 $ (1.3) $ 12.2 $ 13.5 $ (0.1) $ 13.4 State licenses and domain name Indefinite 10.5 — 10.5 7.1 — 7.1 Customer relationships 3.8 13.3 (5.4) 7.9 13.2 (3.8) 9.4 Developed technology 1.3 3.6 (2.3) 1.3 3.6 (1.4) 2.2 VOBA 1.2 0.1 (0.1) — 0.1 — 0.1 Other 5.9 2.3 (0.5) 1.8 1.9 (0.2) 1.7 Total intangible assets, net $ 43.3 $ (9.6) $ 33.7 $ 39.4 $ (5.5) $ 33.9

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	September 30, December 31, (in millions) Accrued wages and commissions $ 6.7 $ 5.0 Deferred revenue 8.5 1.7 Advances from customers 9.1 4.4 Accrued licenses and taxes 7.8 2.5 Accrued transaction cost 2.3 — Warrant liability 9.0 — Other 18.5 12.1 Total accrued expenses and other liabilities $ 61.9 $ 25.7

Loss and Loss Adjustment Expe_2

Loss and Loss Adjustment Expense Reserves (Tables)	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The reconciliation of the beginning and ending reserve balances for losses and loss adjustment expenses, net of reinsurance is summarized as follows for the nine months ended September 30, (in millions): 2021 2020 Reserve for losses and LAE gross of reinsurance recoverables on unpaid losses and LAE as of beginning of the period $ 105.1 $ — Reinsurance recoverables on unpaid losses (92.1) — Reserve for losses and LAE, net of reinsurance recoverables as of beginning of the period 13.0 — Add: Incurred losses and LAE, net of reinsurance, related to: Current year 65.6 13.9 Prior years (0.6) — Total incurred 65.0 13.9 Deduct: Loss and LAE payments, net of reinsurance, related to: Current year 33.5 7.9 Prior year 6.8 — Total paid 40.3 7.9 Reserve for losses and LAE, net of reinsurance recoverables acquired from Spinnaker — 5.0 Reserve for losses and LAE, net of reinsurance recoverables at end of period 37.7 11.0 Add: Reinsurance recoverables on unpaid losses and LAE at end of period 202.0 113.5 Reserve for losses and LAE gross of reinsurance recoverables on unpaid losses and LAE as of end of the period $ 239.7 $ 124.5

Reinsurance (Tables)

Reinsurance (Tables)	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Effects of Reinsurance	The following tables reflect amounts affecting the statements of operations and comprehensive loss for ceded reinsurance for the three and nine months ended September 30, 2021 and 2020 (in millions): For the Three Months Ended September 30, 2021 2020 Written premiums Earned premiums Loss and LAE incurred Written premiums Earned premiums Loss and LAE incurred Direct $ 129.0 $ 98.9 $ 125.4 $ 22.4 $ 21.1 $ 32.0 Assumed — 2.3 4.6 6.5 3.1 5.4 Gross 129.0 101.2 130.0 28.9 24.2 37.4 Ceded (123.1) (90.3) (103.7) (19.0) (19.5) (28.7) Net $ 5.9 $ 10.9 $ 26.3 $ 9.9 $ 4.7 $ 8.7 For the Nine Months Ended September 30, 2021 2020 Written premiums Earned premiums Loss and LAE incurred Written premiums Earned premiums Loss and LAE incurred Direct $ 353.4 $ 253.8 $ 401.5 $ 22.4 $ 21.1 $ 32.0 Assumed 3.3 8.9 14.7 21.1 7.9 10.6 Gross 356.7 262.7 416.2 43.5 29.0 42.6 Ceded (331.5) (232.8) (351.2) (21.0) (20.3) (28.7) Net $ 25.2 $ 29.9 $ 65.0 $ 22.5 $ 8.7 $ 13.9

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Temporary Equity	There were no new issuances of preferred stock during the nine month period ended September 30, 2021, other than the exercise of preferred stock warrants noted below. December 31, 2020 Issuance Price Per Share Authorized Shares Shares Issued and Outstanding Net Carrying Value Liquidation Preference Preferred A-1 Stock $ 0.56965 40,959,815 40,959,815 $ 3.4 $ 3.4 Preferred A-2 Stock 1.57432 48,790,097 48,590,772 10.9 11.0 Preferred B Stock 3.59757 48,326,627 48,326,627 24.9 25.0 Preferred C Stock 7.04471 69,101,902 69,101,895 56.1 70.0 Preferred C-1 Stock 11.74119 17,145,581 — — — Preferred D Stock 15.16420 45,860,183 45,860,183 99.8 100.0 Preferred E Stock 19.66420 53,048,255 53,048,151 149.7 150.0 Total 323,232,460 305,887,443 $ 344.8 $ 359.4

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Activity From Outstanding Instruments Related To Business Acquisition	The below table shows the conversion of Old Hippo’s outstanding instruments on the date of the Closing that were converted, exercised, or issued as stock consideration. Description Balance outstanding prior to the Business Combination Exchange Ratio Post Conversion Balances Old Hippo common stock 15,940,914 6.95433 110,858,374 Old Hippo convertible preferred stock 43,985,178 6.95433 305,887,443 Old Hippo convertible promissory notes 6,247,807 6.95433 43,449,312 Old Hippo preferred stock warrants 2,494,116 6.95433 17,344,906 Old Hippo common stock warrants 3,911,610 6.95433 27,202,571 504,742,606 Less: Repurchase of common stock (9,500,000) Net Old Hippo shares consideration 495,242,606
Share-based Payment Arrangement, Option, Activity	The following table summarizes option activity under the plans: Options Outstanding Weighted-Average Remaining Aggregate Intrinsic Value Number of Shares Weighted Average Exercise Price Contract Term Outstanding as of January 1, 2021 72,205,242 $ 0.70 8.90 $ 108.9 Granted 8,845,569 4.88 Exercised (20,728,860) 0.30 Cancelled/Expired (6,954,384) 0.90 Outstanding as of September 30, 2021 53,367,567 $ 1.52 8.58 $ 178.7 Vested and exercisable as of September 30, 2021 12,945,529 $ 0.69 7.97 $ 51.7
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes-Merton option-pricing model, based on the following inputs: September 30, December 31, Expected term (in years) 5.4 - 6.1 5.6 - 6.1 Expected volatility 29.7% - 30.1% 22.6% - 29.9% Risk-free interest rate 0.6% - 1.0% 0.3% - 1.6% Expected dividend yield — % — %
Share-based Payment Arrangement, Expensed and Capitalized, Amount	Total stock-based compensation expense, classified in the accompanying consolidated statements of operations and comprehensive loss was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Losses and loss adjustment expenses $ 0.1 $ — $ 0.2 $ — Insurance related expenses — 0.1 0.2 0.2 Technology and development 0.8 1.8 1.7 2.3 Sales and marketing 0.9 0.5 3.1 0.8 General and administrative 2.7 10.8 4.6 11.7 Total stock-based compensation expense $ 4.5 $ 13.2 $ 9.8 $ 15.0

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Net loss per share attributable to common stockholders was computed as follows: Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Numerator: Net loss attributable to Hippo – basic and diluted (in millions) $ (30.9) $ (38.6) $ (310.7) $ (87.4) Denominator: Weighted-average shares used in computing net loss per share attributable to Hippo — basic and diluted 386,882,408 87,383,796 175,690,513 85,864,640 Net loss per share attributable to Hippo — basic and diluted $ (0.08) $ (0.44) $ (1.77) $ (1.02)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive are as follows: September 30, 2021 2020 Convertible preferred stock (on an as if converted basis) — 264,641,887 Outstanding options 64,131,579 56,222,150 Warrants to purchase common shares 1,978,022 32,949,982 Warrants to purchase preferred shares — 17,344,912 Common stock subject to repurchase 10,584,764 9,461,880 RSU and PRSUs 23,906 — Total 76,718,271 380,620,811

Geographical Breakdown of Gro_2

Geographical Breakdown of Gross Written Premium (Tables)	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Gross Written Premium by Geographical Areas	Gross written premium (“GWP”) by state is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Amount % of GWP Amount % of GWP Amount % of GWP Amount % of GWP State Texas $ 31.5 24.4 % $ 10.5 36.3 % $ 104.5 29.3 % $ 21.4 49.2 % California 22.6 17.5 % 3.7 12.8 % 64.3 18.0 % 3.7 8.5 % Florida 6.5 5.0 % 1.4 4.8 % 20.9 5.9 % 1.4 3.2 % Georgia 6.2 4.8 % 1.0 3.5 % 16.0 4.5 % 1.4 3.2 % Illinois 6.5 5.0 % 1.3 4.5 % 14.1 4.0 % 2.0 4.6 % Missouri 3.8 2.9 % 1.0 3.5 % 9.7 2.7 % 1.4 3.2 % Colorado 3.8 2.9 % 0.4 1.4 % 9.5 2.7 % 0.4 0.9 % Arizona 3.2 2.5 % 0.4 1.4 % 8.5 2.4 % 0.4 0.9 % New Jersey 2.8 2.2 % 0.7 2.4 % 7.4 2.1 % 0.7 1.6 % Ohio 3.0 2.3 % 1.0 3.5 % 7.9 2.2 % 1.5 3.4 % Other 39.1 30.3 % 7.5 26.0 % 93.9 26.3 % 9.2 21.1 % Total $ 129.0 100 % $ 28.9 100 % $ 356.7 100 % $ 43.5 100 %

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies (Details) - state	9 Months Ended
	Sep. 30, 2021	Aug. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of states licensed as insurance agency	50
Number of states acting as managing general agent with underwriting and distributing of policies	37
Business Acquisition [Line Items]
Reinsured risk, percentage	11.00%
Spinnaker Insurance Company (Spinnaker)
Business Acquisition [Line Items]
Number of states with ability to write commercial and personal line products and licenced property casualty carrier		50

Business Combinations - Reverse

Business Combinations - Reverse Recapitalization (Details) $ / shares in Units, $ in Millions	Aug. 02, 2021USD ($)$ / sharesshares	Aug. 01, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)shares	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)	Dec. 31, 2020shares
Business Acquisition [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	55,000,000
Sale of stock, price per share (in dollars per share) | $ / shares	$ 10
Sale of stock, consideration received on transaction	$ 550
Stock issued during period, shares, business combination			$ 452.9
Exchange ratio	6.95433
Common stock, shares outstanding (in shares) | shares	559,731,226		562,873,880	562,873,880		92,547,014
Proceeds from reverse capitalization, gross	$ 587.7
Cash - PIPE	550			$ 550
Cash in trust, net of redemptions	37.7			37.7
Cash used for repurchase of common stock	95			95
Transaction costs and advisory fees	$ 43.4			43.4
Stock converted, reverse recapitalization (in shares) | shares	495,242,606
Proceeds from the exercise of preferred stock warrants				29	$ 0
Preferred stock warrant liabilities
Business Acquisition [Line Items]
Proceeds from the exercise of preferred stock warrants				$ 29
Old Hippo common stock
Business Acquisition [Line Items]
Repurchase of common stock	$ 95
Repurchase of common stock (in shares) | shares	9,500,000
Exchange ratio	6.95433
Common stock, shares outstanding (in shares) | shares	9,500,000
Founder Shares Class B | Reinvent Sponsor Z LLC | Reinvent Technology Partners Z
Business Acquisition [Line Items]
Stock issued during period, shares, business combination (in shares) | shares	5,750,000	5,750,000
Stock issued during period, shares, business combination		$ 25
Exchange ratio		1
Common Class A
Business Acquisition [Line Items]
Common stock, shares outstanding (in shares) | shares		23,000,000
Common Class A | Reinvent Technology Partners Z
Business Acquisition [Line Items]
Repurchase of common stock		$ 192.6
Repurchase of common stock (in shares) | shares		19,261,380
Stock issued during period, shares, business combination (in shares) | shares	3,738,620
Exchange ratio		1
Repurchase of common stock (in dollars per share) | $ / shares		$ 10

Business Combinations - Element

Business Combinations - Elements of the Business Combination (Details) - USD ($) $ in Millions	Aug. 02, 2021	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Cash in trust, net of redemptions	$ 37.7	$ 37.7
Cash - PIPE	550	550
Less: Cash used for repurchase of common stock	(95)	(95)
Less: transaction costs and advisory fees	$ (43.4)	(43.4)
Net Cash Received from Business Combination and PIPE Investment		$ 449.3

Business Combinations - Issuanc

Business Combinations - Issuance of Common Stock Related to Business Combination (Details)	Aug. 02, 2021shares	Aug. 01, 2021shares	Sep. 30, 2021shares	Dec. 31, 2020shares
Business Acquisition [Line Items]
Common stock, shares outstanding (in shares)	559,731,226		562,873,880	92,547,014
PIPE Shares (in shares)	55,000,000
Business Combination and PIPE shares which converted to Hippo Holding common stock (in shares)	64,488,620
Old Hippo shares, net of repurchase (in shares)	495,242,606
Exchange Ratio	6.95433
Common Class A
Business Acquisition [Line Items]
Common stock, shares outstanding (in shares)		23,000,000
Old Hippo common stock
Business Acquisition [Line Items]
Common stock, shares outstanding (in shares)	9,500,000
Less: Redemption/Repurchase of common stock (in shares)	9,500,000
Exchange Ratio	6.95433
Reinvent Technology Partners Z | Common Class A
Business Acquisition [Line Items]
Less: Redemption/Repurchase of common stock (in shares)		19,261,380
Stock issued during period, shares, business combination (in shares)	3,738,620
Exchange Ratio		1
Reinvent Technology Partners Z | Reinvent Sponsor Z LLC | Founder Shares Class B
Business Acquisition [Line Items]
Stock issued during period, shares, business combination (in shares)	5,750,000	5,750,000
Exchange Ratio		1

Business Combinations - Other A

Business Combinations - Other Acquisitions (Details) - USD ($) $ in Millions	Aug. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 53.2	$ 47.8
Software Development and Engineering Consulting Firm
Business Acquisition [Line Items]
Consideration transferred	$ 7.5
Goodwill	5
Acquired intangibles assets	0.5
Net working capital	2
Acquisition related costs	0.4
Unrecognized compensation cost	$ 5.6
Unrecognized compensation cost, period for recognition	18 months

Investments - Fixed Maturities

Investments - Fixed Maturities Securities and Short-Term Investments (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 60.1	$ 55.9
Unrealized Gains	0	0.1
Unrealized Losses	(0.4)	0
Fair Value	59.7	56
Fair Value	12.3	0
Amortized Cost	72.4
Unrealized Gains	0
Unrealized Losses	(0.4)
Total investments	72	56
U.S. government and agencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	12	10.1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	12	10.1
Amortized Cost	12.3
Unrealized Gains	0
Unrealized Losses	0
Fair Value	12.3
States, and other territories
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5.9	5.1
Unrealized Gains	0	0
Unrealized Losses	(0.1)	0
Fair Value	5.8	5.1
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	18	17.4
Unrealized Gains	0	0
Unrealized Losses	(0.1)	0
Fair Value	17.9	17.4
Foreign securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1.2	0.8
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1.2	0.8
Residential mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	11.7	12.9
Unrealized Gains	0	0
Unrealized Losses	(0.1)	0
Fair Value	11.6	12.9
Commercial mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5	5.4
Unrealized Gains	0	0.1
Unrealized Losses	(0.1)	0
Fair Value	4.9	5.5
Asset backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	6.3	4.2
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 6.3	$ 4.2

Investments - Narrative (Detail

Investments - Narrative (Details)	9 Months Ended
	Sep. 30, 2021USD ($)security	Sep. 30, 2020USD ($)
Investments, Debt and Equity Securities [Abstract]
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, number of positions | security	0
Other than temporary impairment losses, investments | $	$ 0	$ 0

Investments - Contractual Matur

Investments - Contractual Maturity (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
One year or less	$ 10.6
After one year through five years	21.8
After five years	4.6
After ten years	0.1
Amortized Cost	60.1	$ 55.9
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
One year or less	10.6
After one year through five years	21.7
After five years	4.5
After ten years	0.1
Fair Value	59.7	56
Residential mortgage-backed securities
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Securities	11.7
Amortized Cost	11.7	12.9
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Securities	11.6
Fair Value	11.6	12.9
Commercial mortgage-backed securities
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Securities	5
Amortized Cost	5	5.4
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Securities	4.9
Fair Value	4.9	5.5
Asset backed securities
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Securities	6.3
Amortized Cost	6.3	4.2
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Securities	6.3
Fair Value	$ 6.3	$ 4.2

Investments - Net Investment In

Investments - Net Investment Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Fixed maturities income	$ 0.1	$ 0.2	$ 0.3	$ 0.8
Total gross investment income	0.1	0.2	0.3	0.8
Investment expenses	0	0	(0.1)	0
Net investment income	$ 0.1	$ 0.2	$ 0.2	$ 0.8

Investments - Special Deposits

Investments - Special Deposits (Details) $ in Millions	Sep. 30, 2021USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 8.1
Fair Value	8.3
New York
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3.1
Fair Value	3.1
Illinois
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1.6
Fair Value	1.6
Colorado
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1.5
Fair Value	1.6
Virginia
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.3
Fair Value	0.4
North Carolina
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.3
Fair Value	0.3
New Mexico
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.3
Fair Value	0.3
Vermont
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.3
Fair Value	0.3
Florida
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.3
Fair Value	0.3
Nevada
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.2
Fair Value	0.2
Massachusetts
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.1
Fair Value	0.1
Georgia
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	0.1
Fair Value	$ 0.1

Cash, Cash Equivalents, and R_3

Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 778.7	$ 452.3
Restricted cash	44.1	40.1
Total cash, cash equivalents, and restricted cash	822.8	492.4	$ 182.9	$ 42
Cash
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	183.7	56.7
Money market funds
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	595	372.1
Treasury bills
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	0	23.5
Fiduciary assets
Cash and Cash Equivalents [Line Items]
Restricted cash	26	12.1
Letters of credit and cash on deposit
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 18.1	$ 28

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Financial assets:
Cash equivalents	$ 595	$ 395.6
Fixed maturities available-for-sale	59.7	56
Short-term investments	12.3	0
Total financial assets	667	451.6
Financial liabilities:
Derivative liability on convertible promissory notes		113.3
Contingent consideration liability	11.5	12
Warrants liabilities	0	22.9
Total financial liabilities	20.5	148.2
Public warrants
Financial liabilities:
Warrants liabilities	4.2
Private placement warrants
Financial liabilities:
Warrants liabilities	4.8
Preferred stock warrant liabilities
Financial liabilities:
Warrants liabilities		22.9
Level 1
Financial assets:
Cash equivalents	595	395.6
Fixed maturities available-for-sale	12	10.1
Total financial assets	607	405.7
Financial liabilities:
Derivative liability on convertible promissory notes		0
Contingent consideration liability	0	0
Total financial liabilities	4.2	0
Level 1 | Public warrants
Financial liabilities:
Warrants liabilities	4.2
Level 1 | Private placement warrants
Financial liabilities:
Warrants liabilities	0
Level 1 | Preferred stock warrant liabilities
Financial liabilities:
Warrants liabilities		0
Level 2
Financial assets:
Cash equivalents	0	0
Fixed maturities available-for-sale	47.7	45.9
Total financial assets	60	45.9
Financial liabilities:
Derivative liability on convertible promissory notes		0
Contingent consideration liability	0	0
Total financial liabilities	0	0
Level 2 | Public warrants
Financial liabilities:
Warrants liabilities	0
Level 2 | Private placement warrants
Financial liabilities:
Warrants liabilities	0
Level 2 | Preferred stock warrant liabilities
Financial liabilities:
Warrants liabilities		0
Level 3
Financial assets:
Cash equivalents	0	0
Fixed maturities available-for-sale	0	0
Total financial assets	0	0
Financial liabilities:
Derivative liability on convertible promissory notes		113.3
Contingent consideration liability	11.5	12
Total financial liabilities	16.3	148.2
Level 3 | Public warrants
Financial liabilities:
Warrants liabilities	0
Level 3 | Private placement warrants
Financial liabilities:
Warrants liabilities	4.8
Level 3 | Preferred stock warrant liabilities
Financial liabilities:
Warrants liabilities		22.9
U.S. government and agencies
Financial assets:
Fixed maturities available-for-sale	12	10.1
Short-term investments	12.3
U.S. government and agencies | Level 1
Financial assets:
Fixed maturities available-for-sale	12	10.1
Short-term investments	0
U.S. government and agencies | Level 2
Financial assets:
Fixed maturities available-for-sale	0	0
Short-term investments	12.3
U.S. government and agencies | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Short-term investments	0
States, and other territories
Financial assets:
Fixed maturities available-for-sale	5.8	5.1
States, and other territories | Level 1
Financial assets:
Fixed maturities available-for-sale	0	0
States, and other territories | Level 2
Financial assets:
Fixed maturities available-for-sale	5.8	5.1
States, and other territories | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Corporate securities
Financial assets:
Fixed maturities available-for-sale	17.9	17.4
Corporate securities | Level 1
Financial assets:
Fixed maturities available-for-sale	0	0
Corporate securities | Level 2
Financial assets:
Fixed maturities available-for-sale	17.9	17.4
Corporate securities | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Foreign securities
Financial assets:
Fixed maturities available-for-sale	1.2	0.8
Foreign securities | Level 1
Financial assets:
Fixed maturities available-for-sale	0	0
Foreign securities | Level 2
Financial assets:
Fixed maturities available-for-sale	1.2	0.8
Foreign securities | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Residential mortgage-backed securities
Financial assets:
Fixed maturities available-for-sale	11.6	12.9
Residential mortgage-backed securities | Level 1
Financial assets:
Fixed maturities available-for-sale	0	0
Residential mortgage-backed securities | Level 2
Financial assets:
Fixed maturities available-for-sale	11.6	12.9
Residential mortgage-backed securities | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Commercial mortgage-backed securities
Financial assets:
Fixed maturities available-for-sale	4.9	5.5
Commercial mortgage-backed securities | Level 1
Financial assets:
Fixed maturities available-for-sale	0	0
Commercial mortgage-backed securities | Level 2
Financial assets:
Fixed maturities available-for-sale	4.9	5.5
Commercial mortgage-backed securities | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Asset backed securities
Financial assets:
Fixed maturities available-for-sale	6.3	4.2
Asset backed securities | Level 1
Financial assets:
Fixed maturities available-for-sale	0	0
Asset backed securities | Level 2
Financial assets:
Fixed maturities available-for-sale	6.3	4.2
Asset backed securities | Level 3
Financial assets:
Fixed maturities available-for-sale	0	0
Money market funds
Financial assets:
Cash equivalents	595	372.1
Money market funds | Level 1
Financial assets:
Cash equivalents	595	372.1
Money market funds | Level 2
Financial assets:
Cash equivalents	0	0
Money market funds | Level 3
Financial assets:
Cash equivalents	$ 0	0
Treasury bills
Financial assets:
Cash equivalents		23.5
Treasury bills | Level 1
Financial assets:
Cash equivalents		23.5
Treasury bills | Level 2
Financial assets:
Cash equivalents		0
Treasury bills | Level 3
Financial assets:
Cash equivalents		$ 0

Fair Value Measurement - Change

Fair Value Measurement - Changes in Fair Value (Details) - USD ($) $ in Millions	2 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Changes in fair value		$ (5.6)	$ 0
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Liability, beginning balance		12	13.8
Settlement/Payments		(2.6)	(4)
Changes in fair value		2.1	1.9
Liability, ending balance	$ 11.5	11.5	11.7
Embedded Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Liability, beginning balance		113.3
Initial measurement of new derivative		2.8
Settlement/Payments		(177.5)
Changes in fair value		61.4
Liability, ending balance	0	0
Preferred Stock Warrant
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Liability, beginning balance		22.9	6.7
Changes in fair value		121.6	4.2
Settlement/Payments		(144.5)	0
Liability, ending balance	0	0	$ 10.9
Warrant liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Liability, beginning balance	14.6
Changes in fair value	(5.6)
Liability, ending balance	$ 9	$ 9

Fair Value Measurement - Narrat

Fair Value Measurement - Narrative (Details)	Aug. 02, 2021	Sep. 30, 2021
Discount rate | Income approach
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Convertible promissory notes, measurement input		0.10
Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Convertible promissory notes, conversion period	0 years
Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Convertible promissory notes, conversion period	2 years 7 months 6 days

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions (Details) - Private warrant	Sep. 30, 2021$ / shares
Temporary Equity [Line Items]
Remaining term (years)	4 years 10 months 2 days
Stock price
Temporary Equity [Line Items]
Measurement input	4.68
Strike price
Temporary Equity [Line Items]
Measurement input	11.50
Risk free rate
Temporary Equity [Line Items]
Measurement input	0.010
Volatility
Temporary Equity [Line Items]
Measurement input	0.540

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (9.6)		$ (9.6)		$ (5.5)
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount	43.3		43.3		39.4
Accumulated Amortization	(9.6)		(9.6)		(5.5)
Net Carrying Amount	33.7		33.7		33.9
Amortization expense related to intangible assets	1.3	$ 0.9	4.1	$ 2.7
State licenses and domain name
Indefinite-lived Intangible Assets [Line Items]
Net Carrying Amount	10.5		$ 10.5		7.1
Agency and carrier relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Useful Life Remaining (in years)			7 years 8 months 12 days
Gross Carrying Amount	13.5		$ 13.5		13.5
Accumulated Amortization	(1.3)		(1.3)		(0.1)
Net Carrying Amount	12.2		12.2		13.4
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	(1.3)		$ (1.3)		(0.1)
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Useful Life Remaining (in years)			3 years 9 months 18 days
Gross Carrying Amount	13.3		$ 13.3		13.2
Accumulated Amortization	(5.4)		(5.4)		(3.8)
Net Carrying Amount	7.9		7.9		9.4
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	(5.4)		$ (5.4)		(3.8)
Developed technology
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Useful Life Remaining (in years)			1 year 3 months 18 days
Gross Carrying Amount	3.6		$ 3.6		3.6
Accumulated Amortization	(2.3)		(2.3)		(1.4)
Net Carrying Amount	1.3		1.3		2.2
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	(2.3)		$ (2.3)		(1.4)
VOBA
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Useful Life Remaining (in years)			1 year 2 months 12 days
Gross Carrying Amount	0.1		$ 0.1		0.1
Accumulated Amortization	(0.1)		(0.1)		0
Net Carrying Amount	0		0		0.1
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	(0.1)		$ (0.1)		0
Other
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Useful Life Remaining (in years)			5 years 10 months 24 days
Gross Carrying Amount	2.3		$ 2.3		1.9
Accumulated Amortization	(0.5)		(0.5)		(0.2)
Net Carrying Amount	1.8		1.8		1.7
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	$ (0.5)		$ (0.5)		$ (0.2)

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued wages and commissions	$ 6.7	$ 5
Deferred revenue	8.5	1.7
Advances from customers	9.1	4.4
Accrued licenses and taxes	7.8	2.5
Accrued transaction cost	2.3	0
Warrant liability	9	0
Other	18.5	12.1
Total accrued expenses and other liabilities	$ 61.9	$ 25.7

Loss and Loss Adjustment Expe_3

Loss and Loss Adjustment Expense Reserves (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Reserve for losses and LAE gross of reinsurance recoverables on unpaid losses and LAE as of beginning of the period			$ 105.1	$ 0
Reinsurance recoverables on unpaid losses			(92.1)	0
Reserve for losses and LAE, net of reinsurance recoverables as of beginning of the period			13	0
Add: Incurred losses and LAE, net of reinsurance, related to:
Current year			65.6	13.9
Prior years			(0.6)	0
Total incurred	$ 26.3	$ 8.7	65	13.9
Deduct: Loss and LAE payments, net of reinsurance, related to:
Current year			33.5	7.9
Prior year			6.8	0
Total paid			40.3	7.9
Reserve for losses and LAE, net of reinsurance recoverables at end of period	37.7	11	37.7	11
Add: Reinsurance recoverables on unpaid losses and LAE at end of period	202	113.5	202	113.5
Reserve for losses and LAE gross of reinsurance recoverables on unpaid losses and LAE as of end of the period	$ 239.7	$ 124.5	239.7	124.5
Spinnaker Insurance Company (Spinnaker)
Deduct: Loss and LAE payments, net of reinsurance, related to:
Reserve for losses and LAE, net of reinsurance recoverables acquired from Spinnaker			$ 0	$ 5

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)reinsurer	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)reinsurer	Sep. 30, 2020USD ($)
Effects of Reinsurance [Line Items]
Loss on uncollectible accounts in period | $	$ 0	$ 0	$ 0	$ 0
Number of third-party reinsures	9		9
Reinsured risk, percentage			11.00%
Term-based agreement
Effects of Reinsurance [Line Items]
Number of third-party reinsures	2		2
Percentage attributable to program	33.00%		33.00%
Agreement term			3 years

Reinsurance - Ceded Reinsurance

Reinsurance - Ceded Reinsurance (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Written premiums
Direct	$ 129	$ 22.4	$ 353.4	$ 22.4
Assumed	0	6.5	3.3	21.1
Gross	129	28.9	356.7	43.5
Ceded	(123.1)	(19)	(331.5)	(21)
Net	5.9	9.9	25.2	22.5
Earned premiums
Direct	98.9	21.1	253.8	21.1
Assumed	2.3	3.1	8.9	7.9
Gross	101.2	24.2	262.7	29
Ceded	(90.3)	(19.5)	(232.8)	(20.3)
Net	10.9	4.7	29.9	8.7
Loss and LAE incurred
Direct	125.4	32	401.5	32
Assumed	4.6	5.4	14.7	10.6
Gross	130	37.4	416.2	42.6
Ceded	(103.7)	(28.7)	(351.2)	(28.7)
Net	$ 26.3	$ 8.7	$ 65	$ 13.9

Convertible Promissory Notes _2

Convertible Promissory Notes and Derivative Liability (Details) $ in Millions	Aug. 02, 2021USD ($)shares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Convertible promissory notes		$ 0		$ 273
Derivative liability		0		$ 113.3
Gain on extinguishment of debt		47	$ 0
Convertible promissory note
Debt Instrument [Line Items]
Face amount		$ 384.5
Interest rate		2.50%
Fair value of embedded derivatives		$ 110
Threshold percentage of stock price trigger		90.00%
Convertible promissory notes	$ 302.3
Deferred discount and issuance costs	86.9
Derivative liability	177.5
Gain on extinguishment of debt	$ 47
Convertible promissory note | Common Stock
Debt Instrument [Line Items]
Convertible, number of equity instruments (in shares) | shares	43,449,312
Convertible promissory note | Conversion event has not occurred
Debt Instrument [Line Items]
Interest rate, increase (decrease)		2.50%
Interest rate, stated percentage, maximum after rate increase		7.50%
Convertible promissory note | Conversion event has not occurred, 15 month after
Debt Instrument [Line Items]
Interest rate, stated percentage, maximum after rate increase		5.00%
Interest rate adjustment, period after issuance		15 months
Convertible promissory note | Conversion event has not occurred, 21 month after
Debt Instrument [Line Items]
Interest rate, stated percentage, maximum after rate increase		5.00%
Interest rate adjustment, period after issuance		21 months

Public Warrants and Private P_2

Public Warrants and Private Placement Warrants - Narrative (Details) - Reinvent Technology Partners Z	Nov. 30, 2020$ / sharesshares
Public warrants
Class of Warrant or Right [Line Items]
Warrant shares outstanding (in shares) | shares	4,600,000
Private placement warrants
Class of Warrant or Right [Line Items]
Warrant shares outstanding (in shares) | shares	4,400,000
Common stock warrant
Class of Warrant or Right [Line Items]
Conversion ratio	1
Common Class A | Public warrants
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 11.50
Common Class A | Private placement warrants
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 11.50

Commitment and Contingencies (D

Commitment and Contingencies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 0.8	$ 0.7	$ 2.2	$ 2.1
Texas
Lessee, Lease, Description [Line Items]
Lessee, operating lease, liability, to be paid	$ 8		$ 8

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) - shares	Aug. 02, 2021	Sep. 30, 2021	Aug. 31, 2021	Oct. 31, 2018	Mar. 31, 2017
Preferred A-2 Stock
Temporary Equity [Line Items]
Warrant shares outstanding (in shares)					28,662
Preferred C-1 Stock
Temporary Equity [Line Items]
Warrant shares outstanding (in shares)				2,465,454
Convertible Preferred Stock
Temporary Equity [Line Items]
Issuances during period (in shares)		0
Number of securities called by warrants or rights (in shares)			2,494,116
Common Stock
Temporary Equity [Line Items]
Convertible preferred stock conversion (in shares)	323,232,349
Number of securities called by each warrants or rights (in shares)			17,344,906

Convertible Preferred Stock - C

Convertible Preferred Stock - Components (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Temporary Equity [Line Items]
Authorized Shares (in shares)	10,000,000			323,232,460
Shares Issued (in shares)	0			305,887,443
Shares Outstanding (in shares)	0	305,887,443	305,887,443	305,887,443	305,887,443	252,839,292	252,839,292	250,604,066
Net Carrying Value	$ 0	$ 344.8	$ 344.8	$ 344.8	$ 344.8	$ 195.2	$ 195.2	$ 190.3
Liquidation Preference	$ 0			$ 359.4
Preferred A-1 Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 0.56965
Authorized Shares (in shares)				40,959,815
Shares Issued (in shares)				40,959,815
Shares Outstanding (in shares)				40,959,815
Net Carrying Value				$ 3.4
Liquidation Preference				$ 3.4
Preferred A-2 Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 1.57432
Authorized Shares (in shares)				48,790,097
Shares Issued (in shares)				48,590,772
Shares Outstanding (in shares)				48,590,772
Net Carrying Value				$ 10.9
Liquidation Preference				$ 11
Preferred B Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 3.59757
Authorized Shares (in shares)				48,326,627
Shares Issued (in shares)				48,326,627
Shares Outstanding (in shares)				48,326,627
Net Carrying Value				$ 24.9
Liquidation Preference				$ 25
Preferred C Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 7.04471
Authorized Shares (in shares)				69,101,902
Shares Issued (in shares)				69,101,895
Shares Outstanding (in shares)				69,101,895
Net Carrying Value				$ 56.1
Liquidation Preference				$ 70
Preferred C-1 Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 11.74119
Authorized Shares (in shares)				17,145,581
Shares Issued (in shares)				0
Shares Outstanding (in shares)				0
Net Carrying Value				$ 0
Liquidation Preference				$ 0
Preferred D Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 15.16420
Authorized Shares (in shares)				45,860,183
Shares Issued (in shares)				45,860,183
Shares Outstanding (in shares)				45,860,183
Net Carrying Value				$ 99.8
Liquidation Preference				$ 100
Preferred E Stock
Temporary Equity [Line Items]
Issuance Price Per Share (in dollars per share)				$ 19.66420
Authorized Shares (in shares)				53,048,255
Shares Issued (in shares)				53,048,151
Shares Outstanding (in shares)				53,048,151
Net Carrying Value				$ 149.7
Liquidation Preference				$ 150

Stockholders_ Equity - Narrativ

Stockholders’ Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 02, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Aug. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000	2,000,000,000			582,981,484
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001
Stock converted, reverse recapitalization (in shares)	495,242,606
Sale of stock, number of shares issued in transaction (in shares)	55,000,000
Sale of stock, consideration received on transaction	$ 550
Aggregate intrinsic value of options exercised			$ 35.7	$ 3.5
Weighted average grant date, fair value (in dollars per share)			$ 2.24	$ 1.97
Exercises in period, forgiveness (in shares)	9,400,000
Exercises in period, forgiveness, intrinsic value	$ 94
Incremental stock option charge, number of shares subject to repurchase (in shares)		3,534,296	3,534,296
Early exercise of stock options liability for unvested awards		$ 2.4	$ 2.4			$ 2.5
Number of shares subject to repurchase related to early exercise of stock option (in shares)		2,231,896	2,231,896			2,399,245
the 2019 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent			100.00%
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Number of shares authorized for issuance (in shares)	78,000,000
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock converted, reverse recapitalization (in shares)	495,242,606
Number of securities called by each warrants or rights (in shares)					17,344,906
Common stock warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities called by warrants or rights (in shares)	3,911,610
Common stock warrant | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities called by each warrants or rights (in shares)	27,202,571
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		$ 37.5	$ 37.5
Unrecognized compensation cost, period for recognition			2 years 7 months 6 days
Expected term			10 years
Incremental stock option charge		2.1
Options | the 2019 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term period			10 years
Vesting period			4 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Unrecognized compensation cost		$ 1	$ 1
Unrecognized compensation cost, period for recognition			3 years 10 months 24 days
Outstanding in period (in shares)		210,526	210,526
Nonvested, weighted average grant date fair value (in dollars per share)		$ 5.28	$ 5.28
RSUs | the 2019 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Performance Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			18 months
Unrecognized compensation cost		$ 6.7	$ 6.7
Unrecognized compensation cost, period for recognition			18 months
Outstanding in period (in shares)		1,269,388	1,269,388
Nonvested, weighted average grant date fair value (in dollars per share)		$ 5.28	$ 5.28
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in shares)		13,000,000	13,000,000

Stockholders_ Equity - Instrume

Stockholders’ Equity - Instrument Activity Related to Business Acquisition (Details)	Aug. 02, 2021shares	Aug. 01, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares)	504,742,606
Exchange Ratio	6.95433
Old Hippo shares, net of repurchase (in shares)	495,242,606
Old Hippo preferred stock warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares)	17,344,906	2,494,116
Exchange Ratio	6.95433
Old Hippo common stock warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares)	27,202,571	3,911,610
Exchange Ratio	6.95433
Old Hippo common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares)	110,858,374	15,940,914
Exchange Ratio	6.95433
Less: Repurchase of common stock (in shares)	(9,500,000)
Old Hippo convertible preferred stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares)	305,887,443	43,985,178
Exchange Ratio	6.95433
Old Hippo convertible promissory notes | Old Hippo convertible promissory notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares)	43,449,312	6,247,807
Exchange Ratio	6.95433
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Less: Repurchase of common stock (in shares)	(9,500,000)
Old Hippo shares, net of repurchase (in shares)	495,242,606

Stockholders_ Equity - Stock Op

Stockholders’ Equity - Stock Option Activity (Details) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Options Outstanding
Outstanding, beginning balance (in shares) | shares	72,205,242
Granted (in shares) | shares	8,845,569
Exercise of stock options (in shares) | shares	20,728,860
Cancelled/Expired (in shares) | shares	(6,954,384)
Outstanding, ending balance (in shares) | shares	53,367,567	72,205,242
Vested and exercisable (in shares) | shares	12,945,529
Weighted Average Exercise Price
Outstanding, beginning balance (in dollar per share) | $ / shares	$ 0.70
Granted (in dollars per share) | $ / shares	4.88
Exercised (in dollars per share) | $ / shares	0.30
Cancelled/Expired (in dollars per share) | $ / shares	0.90
Outstanding, ending balance (in dollar per share) | $ / shares	1.52	$ 0.70
Vested and exercisable (in dollars per share) | $ / shares	$ 0.69
Additional Disclosures
Outstanding, weighted-average remaining, contract term (in years)	8 years 6 months 29 days	8 years 10 months 24 days
Outstanding, aggregate intrinsic value | $	$ 178.7	$ 108.9
Vested and exercisable, weighted-average remaining, contract term (in years)	7 years 11 months 19 days
Vested and exercisable, aggregate intrinsic value | $	$ 51.7

Stockholders_ Equity - Stock _2

Stockholders’ Equity - Stock Option Assumptions (Details) - Options	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years
Expected volatility, minimum	29.70%	22.60%
Expected volatility, maximum	30.10%	29.90%
Risk-free interest rate, minimum	0.60%	0.30%
Risk-free interest rate, maximum	1.00%	1.60%
Expected dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 4 months 24 days	5 years 7 months 6 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days

Stockholders_ Equity - Share-ba

Stockholders’ Equity - Share-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 4.5	$ 13.2	$ 9.8	$ 15
Losses and loss adjustment expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.1	0	0.2	0
Insurance related expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0	0.1	0.2	0.2
Technology and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.8	1.8	1.7	2.3
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.9	0.5	3.1	0.8
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 2.7	$ 10.8	$ 4.6	$ 11.7

Income Taxes (Details)

Income Taxes (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	(0.10%)	2.10%
Unrecognized tax benefits	$ 0	$ 0
Income tax interest or penalties incurred	$ 0	$ 0

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss attributable to Hippo - basic	$ (30.9)	$ (38.6)	$ (310.7)	$ (87.4)
Net loss attributable to Hippo - diluted	$ (30.9)	$ (38.6)	$ (310.7)	$ (87.4)
Weighted-average shares used in computing net loss per share attributable to Hippo - basic (in shares)	386,882,408	87,383,796	175,690,513	85,864,640
Weighted-average shares used in computing net loss per share attributable to Hippo - diluted (in shares)	386,882,408	87,383,796	175,690,513	85,864,640
Net loss per share attributable to Hippo - basic (in dollars per share)	$ (0.08)	$ (0.44)	$ (1.77)	$ (1.02)
Net loss per share attributable to Hippo - diluted (in dollars per share)	$ (0.08)	$ (0.44)	$ (1.77)	$ (1.02)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	76,718,271	380,620,811
Convertible preferred stock (on an as if converted basis)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	264,641,887
Outstanding options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	64,131,579	56,222,150
Warrants to purchase common shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,978,022	32,949,982
Warrants to purchase preferred shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	17,344,912
Common stock subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	10,584,764	9,461,880
RSU and PRSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	23,906	0

Geographical Breakdown of Gro_3

Geographical Breakdown of Gross Written Premium (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Gross Written Premium [Line Items]
Amount	$ 129	$ 28.9	$ 356.7	$ 43.5
Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Texas
Gross Written Premium [Line Items]
Amount	$ 31.5	$ 10.5	$ 104.5	$ 21.4
Texas | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	24.40%	36.30%	29.30%	49.20%
California
Gross Written Premium [Line Items]
Amount	$ 22.6	$ 3.7	$ 64.3	$ 3.7
California | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	17.50%	12.80%	18.00%	8.50%
Florida
Gross Written Premium [Line Items]
Amount	$ 6.5	$ 1.4	$ 20.9	$ 1.4
Florida | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	5.00%	4.80%	5.90%	3.20%
Georgia
Gross Written Premium [Line Items]
Amount	$ 6.2	$ 1	$ 16	$ 1.4
Georgia | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	4.80%	3.50%	4.50%	3.20%
Illinois
Gross Written Premium [Line Items]
Amount	$ 6.5	$ 1.3	$ 14.1	$ 2
Illinois | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	5.00%	4.50%	4.00%	4.60%
Missouri
Gross Written Premium [Line Items]
Amount	$ 3.8	$ 1	$ 9.7	$ 1.4
Missouri | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	2.90%	3.50%	2.70%	3.20%
Colorado
Gross Written Premium [Line Items]
Amount	$ 3.8	$ 0.4	$ 9.5	$ 0.4
Colorado | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	2.90%	1.40%	2.70%	0.90%
Arizona
Gross Written Premium [Line Items]
Amount	$ 3.2	$ 0.4	$ 8.5	$ 0.4
Arizona | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	2.50%	1.40%	2.40%	0.90%
New Jersey
Gross Written Premium [Line Items]
Amount	$ 2.8	$ 0.7	$ 7.4	$ 0.7
New Jersey | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	2.20%	2.40%	2.10%	1.60%
Ohio
Gross Written Premium [Line Items]
Amount	$ 3	$ 1	$ 7.9	$ 1.5
Ohio | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	2.30%	3.50%	2.20%	3.40%
Other
Gross Written Premium [Line Items]
Amount	$ 39.1	$ 7.5	$ 93.9	$ 9.2
Other | Geographic Concentration Risk | Gross written premium
Gross Written Premium [Line Items]
Concentration risk, percentage	30.30%	26.00%	26.30%	21.10%